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AFP  alpha fetoprotein
AMD473  picoplatin, [cis-amminedichloro (2-methylpyridine) platinum]
ASCO  American Society of Clinical Oncology 
AUC  area under the curve
BRL 43694  granisetron
CHIP  see JM9
Cisplatin cis-dichlorodiammineplatinum II
FDA  Food and Drug Administration
GFR  glomerular filtration rate
GR 38032F  later ondansetron, or Zofran®
HPLC  high pressure liquid chromatography
5HT   5-hydroxytryptamine
ICS 205-930  tropisetron
JM  Johnson Matthey
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JM9  iproplatin, cis-dichlorobis (isopropylamine) trans-
dihydroxyplatinum (IV) 
MRC      Medical Research Council
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NIH    National Institutes of Health
OPB  Paediatric Oncology Group of Benelux
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SIOPEL  International Childhood Liver Tumour Strategy Group
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WiTness seminars: 
MEETINGS AND PUBLICATIONS 1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the Academic Unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential benefits 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic affiliation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome 
Trust continues to fund the Witness Seminar programme via its support for 
the Centre.
The Witness Seminar is a particularly specialized form of oral history, where 
several people associated with a particular set of circumstances or events are 
invited to come together to discuss, debate, and agree or disagree about their 
memories. To date, the History of Twentieth Century Medicine Group has 
held nearly 50 such meetings, most of which have been published, as listed on 
pages xvi–xx. 
Subjects are usually proposed by, or through, members of the Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been 
agreed, suitable participants are identified and invited. This inevitably leads to 
further contacts, and more suggestions of people to invite. As the organization 
of the meeting progresses, a flexible outline plan for the meeting is devised, 
usually with assistance from the meeting’s chairman, and some participants are 
invited to ‘set the ball rolling’ on particular themes, by speaking for a short 
period to initiate and stimulate further discussion.
1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of 
Medicine at UCL.
xmembers of the programme committee of the  
history of Twentieth century medicine group, 2006–07
Dr Tilli Tansey – Reader in History of Modern Medical Sciences, Wellcome Trust Centre 
for the History of Medicine at UCL (WTCHM) and Chair
sir christopher Booth – WTCHM, former Director, Clinical Research Centre,  
Northwick Park Hospital, London
Dr robert Bud – Principal Curator of Medicine and Manager of Electronic 
Content, Science Museum, London
Dr Daphne christie – Senior Research Assistant, WTCHM, and Organizing Secretary
Dr John ford – Retired General Practitioner, Tonbridge 
professor mark Jackson – Centre for Medical History, Exeter
professor ian mcDonald
†
 – WTCHM, former Professor of Neurology, Institute of 
Neurology, London
Dr helga satzinger – Reader in History of Twentieth Century Biomedicine, WTCHM
professor lawrence Weaver – Professor of Child Health, University of Glasgow, and 
Consultant Paediatrician in the Royal Hospital for Sick Children, Glasgow
Each meeting is fully recorded, the tapes are transcribed and the unedited 
transcript is immediately sent to every participant. Each is asked to check his 
or her own contributions and to provide brief biographical details. The editors 
turn the transcript into readable text, and participants’ minor corrections and 
comments are incorporated into that text, while biographical and bibliographical 
details are added as footnotes, as are more substantial comments and additional 
material provided by participants. The final scripts are then sent to every 
contributor, accompanied by forms assigning copyright to the Wellcome Trust. 
Copies of all additional correspondence received during the editorial process 
are deposited with the records of each meeting in Archives and Manuscripts, 
Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
 
†Died 13 December 2006 
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Platinum is one of many medically useful metals, possibly the key example. 
Upon the invitation of the Chairman, Kenneth Calman, Andrew Thomson 
described the fascinating story of the laboratory where Barney Rosenberg, with 
his technician Loretta Van Camp, made the discovery that led ultimately to 
the development of platinum salts as anticancer agents. The development of 
this class of agents, as Robert Williams rightly points out, was not immediately 
perceived as useful, rather the opposite. He suggests that the Americans were 
scared stiff of platinum drugs and would not let them be tested in any hospital 
under NIH control (page 19). The development of anticancer drugs is full 
of such stories. For example, overcoming the allergic reactions that initially 
led to paclitaxel being shelved took some persistence,1 and prior to that, the 
understanding that etoposide had to be given on repeated days to be active was 
a similar example.2 
The development of cisplatin was slowed by two issues: nephrotoxicity and emesis. 
Eve Wiltshaw and others describe how the early observations of remarkable 
antitumour activity encouraged some clinicians to continue the development of 
the drug, which others discarded (pages 24–26). Almost in parallel, carboplatin 
was developed, and became one of the rare drugs that an oncologist can use in 
an ‘intelligent’ way, where the dose is adapted to renal function, nicely described 
by Hilary Calvert, whose formula is well known (page 28, note 68). Richard 
Gralla pays appropriate tribute to Esteban (Steve) Cvitkovic, whose intelligent 
persistence was key in the development of the hydration schemes that allow the 
use of medium- and high-dose cisplatin safely (pages 31–32). 
Cisplatin was the key drug prompting the need to develop effective antiemetic 
agents, another fascinating story related by Paul Andrews and others (pages 44–45). 
Today’s nursing and medical staff cannot imagine what an oncology outpatient 
service, let alone the inpatient ward, was like in the late 1970s and early 1980s (page 
42). The contributions in this volume correctly highlight the incredible debate 
about the cost of new effective antiemetics: ‘comfort drugs’ that were ‘ruining the 
NHS’ (page 61). Cured patients can still feel, years later, that the drug that saved 
their life has left its own mark in their body, mainly in terms of ototoxicity and 
 
1 Adams et al. (1993).
2 Cavalli (1982).
xxiv
neurotoxicity. But while one needs to take these difficulties into account, they 
are not sufficient reason to cease using cisplatin, to which so many patients owe 
their life.3
But while it can be argued today that cisplatin and other platinums, like carboplatin 
and oxaliplatin, play a major role in oncology, will they disappear the way other 
‘medical metals’ have done, or are they just as ‘essential’ as potassium? Thinking 
of the most precious metals, after platinum, one has immediately to cite silver and 
gold (the ‘noble’ metals). Until recently Silver has played a major role in medicine, 
as part of the coating of films used to capture X-ray images, and more modern 
radiographs. The electronic age has meant its almost complete disappearance, as 
digitalized image processing is becoming standard. Gold was used in medicine 
for rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, and 
several other diseases, but nowadays is rarely used, except in some cases which 
are unresponsive to non-steroidal anti-inflammatory drugs, or methotrexate (see 
Kenneth Calman’s ‘praise poem’ in this volume, pages 78–81).4 Arsenic has a long 
history of medical use, and came to prominence in the early twentieth century as 
a component of Salvarsan and Neosalvarsan as treatments for syphilis. Discovered 
in the laboratory of Paul Ehrlich in Frankfurt, Germany, these treatments were 
the result of the first organized team effort to optimize the biological activity 
of compounds through systematic chemical modifications. This is considered by 
many to be the basis of modern pharmaceutical research. More recently, another 
arsenic-based agent has entered the oncohaematological field: arsenic trioxide 
(was it actually Madame Bovary’s poison?) is used to treat acute promyelocytic 
leukaemia resistant to all-trans retinoic acid.5 Boron still has some place in the 
treatment of glioblastoma multiforme),6 but mercury, once the mainstay of 
antisyphilis treatment, is basically banned nowadays, after having caused disasters 
like the one in Minamata Bay.7 However, mercury is still used in some vaccine 
preparations as a conservative agent (thiomersal) and in dental amalgams.8
3  For example, the use of neomycin instead of streptomycin in which the patient was cured of his infection 
but was stone deaf after his treatment, see Tansey and Reynolds (eds) (2000): 23.
4 See also Eisler (2003).
5 See, for example, Flaubert (1998); Zhu et al. (2002). See also Christie and Tansey (eds) (2003): 
10, 13, 20.
6 Barth and Joensuu (2007).
7 See Harada (1995); Christie and Tansey (eds) (2004): 36–7.
8 Marks and Beatty (1975). 
xxv
Bringing together many of those involved in the development of the platinum 
compounds in oncology, this Witness Seminar is a remarkable resource for the 
study of modern medical history. Let us hope many more such seminars will 
enlighten us.
matti aapro,  
Genolier, Switzerland
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3
Dr Tilli Tansey: Good afternoon, ladies and gentlemen. May I welcome you to this 
Witness Seminar on platinum compounds? I am the Convenor of the History of 
Twentieth Century Medicine Group. This was established by the Wellcome Trust 
in 1990 to bring together clinicians, scientists, historians of medicine and others 
interested in what we call the recent history of medicine; that is, post-Second 
World War. We devised a number of strategies to reach this objective, including 
this format of Witness Seminars, where we gather together a group of people 
who have been involved in a particular discovery, or a development, and get 
them to talk, candidly we hope, in a chairman-led discussion. The proceedings 
of this are recorded, and the transcripts are edited and published.1
This meeting came about because of a suggestion made to me by Mark Walport, 
Director of the Wellcome Trust, and it tied in with a suggestion that I had 
been discussing with Paul Andrews from St George’s Hospital Medical School, 
University of London, and Tony Woods, also of the Wellcome Trust.2 I had 
been talking with Paul and Tony about having a meeting on antiemetics, and 
it seemed to be a very good idea to combine both ideas in this one meeting. 
Of course, metals in medicine have a very long history; you need only think of 
things like arsenic and mercury.3 But it wasn’t until 1965 that Barnett Rosenberg, 
in a study looking at the effect of electrical currents on cultured bacteria, 
noticed that he could get growth inhibition around his platinum electrodes.4 
He said rather laconically in reminiscence, that he made the intuitive step of 
testing the platinum compounds as an anticancer agent on cell tissue cultures.5 
This led to the rapid development of more than 2000 compounds which were 
tested by Bristol-Myers [NY, USA] for example, and in 1971 some platinum 
compounds first went into clinical trials in the US. Barnett Rosenberg worked 
on platinum analogues at Michigan State University (MSU) in East Lansing 
1 All volumes of Wellcome Witnesses to Twentieth Century Medicine are freely available to download 
at www.ucl.ac.uk/histmed, following the links to Publications/Wellcome Witnesses. For a list see 
pages xvi–xx.
2 Dr Mark Walport was appointed Director of the Wellcome Trust in June 2003. Dr Tony Woods is Head of 
Medicine, Society and History Grants, Wellcome Trust. Professor Paul Andrews is Professor of Comparative 
Physiology at St George’s Hospital Medical School, London (see page 98).
3 See, for example, Graeme and Pollack (1998). See also Introduction, page xxiv. 
4 Professor Andrew Thomson wrote: ‘Cis-platin [cis-diamminedichloroplatinum (II)] was identified in the 
laboratory of Barnett Rosenberg as one of the agents responsible for the filamentous forms of bacteria 
observed after applying an electric current between platinum electrodes. See Rosenberg et al. (1965, 1967a).’ 
Letter to Dr Daphne Christie, 18 February 2007.
5 See Rosenberg (1978).
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with commercial partners and research corporations, and in this country with 
the cancer institution, the Royal Marsden, at Sutton, and Johnson Matthey 
(JM),6 all looked at platinum analogues. Of these, cisplatinum7 was a very 
active chemotherapeutic, but it had problems, nephrotoxicity and neurotoxicity 
problems, and there was also the problem of platinum resistance.8 Another 
major problem was that of emesis – severe nausea and vomiting in response to 
platinum compounds – which led, particularly in the 1980s, to an upsurge of 
interest in the physiology and pharmacology of nausea and vomiting, and in the 
mid-1980s to the identification of the 5HT3 receptor antagonists.
9 
I believe this is the first time that we have had representatives from all stages 
of that history together in one room, so we are looking forward to hearing the 
debate and discussion that will emerge this afternoon. In addition to identifying 
and locating participants to take part in this meeting, we spent a long time 
thinking about who could chair the meeting, and we are delighted that Sir 
Kenneth Calman has been able to accept our invitation. Sir Kenneth was Chief 
Medical Officer for Scotland and for England, and is now the Vice-Chancellor 
of the University of Durham, but he started his career as a lecturer in oncology 
at the University of Glasgow, as a research fellow at the Chester Beatty Research 
Institute, later becoming Professor of Oncology and Postgraduate Dean at the 
University of Glasgow. Among his unpublished works is a poem in praise of 
methotrexate. If I can just quote from it:10 
Get big cell kill from fluorouracil,  
be a medicine man with melphalan, 
keep things pristine with vincristine, 
shout with glee with 6MP…
but, and this is important for today, 
you can flatten ’em, with platinum. 
6 Johnson Matthey is a specialist chemicals company and a world leader in advanced materials technology. 
It was founded as a precious metals assayer in 1817 and is now the world’s largest fabricator and distributor 
of platinum group metals; it developed the platinum-based anticancer drugs, cisplatin and carboplatin. For 
a history, see www.matthey.com/about/history.htm (visited 29 November 2006). See also www.chemcases.
com/cisplat/index.htm (visited 15 March 2007).
7 Cisplatinum, cis-dichlorodiammineplatinum (II) is also referred to as cisplatin or cis-platin in 
the transcript.
8 See, for example, Cleare and Hoeschele (1973b); Judson (1993): 45–58; Kelland et al. (1999).
9 For example, ondansetron, granisetron and tropisetron (see Appendix 2). This is discussed later on 
pages 44–5, 46 and 49–69. See, for example, Hesketh et al. (1989); van Wijngaarden et al. (1993).
10 Professor Sir Kenneth Calman’s complete poem is given in Appendix 1.
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I think that’s a very suitable sentiment to introduce our Chairman, Sir 
Kenneth Calman.
professor sir kenneth calman: Thank you very much. The poem was 
written in praise of methotrexate, and the verse, I think, is, ‘You can fix it 
with methotrexate’. 
I am delighted to be here and, as Tilli has said, I had an MRC fellowship at 
the Chester Beatty with one or two distinguished people around this room 
in 1972 and went back to be Professor of Oncology in Glasgow in 1974, at 
a ridiculously early age, which would never happen now, and, as Professor 
Bagshawe has already reminded me, as a surgeon at the time doing vascular and 
transplant surgery, and to become a Professor of Medical Oncology wasn’t all 
that difficult at the time. 
Things that you can’t do now are interesting: I suspect that one of the themes 
that has repeatedly arisen in a number of these Witness Seminars in the past 
has been that ‘you couldn’t quite do it now’.11 One of the issues I think, for the 
Wellcome Trust and other funders, is how do you fund a Barnett Rosenberg? 
To think he should just try platinum on cancer cells; it just doesn’t happen that 
way any more, we have to be so prescriptive, sometimes, in terms of research 
funding. But that’s just a small personal observation, which no doubt some of 
you will want to pick up on. 
When I began in 1974, very few patients, if any, were referred for anything like 
testicular or ovarian disease of a teratomatous nature. When I left in 1984, we 
had a significant series of patients, and cisplatin was a remarkable, and effective 
drug. In the audience today, we have a patient who was treated in the early 
1980s.12 Suddenly things changed. You could do things with patients, which 
would make a huge difference to their long-term survival, although in the short-
term it was quite difficult in terms of the side-effects, particularly vomiting. 
But the other thing that was very important for me – and we’ll perhaps pick this 
up at the end of this meeting – is what I have called the ‘wider implications’. 
Not only was this an effective treatment for a disease that was difficult to treat, 
but we were dealing with young people, particularly young men in Glasgow, 
as it happened, who needed to know what was going on. When I arrived in 
11 A list of Witness Seminars is given on pages xiii–xv.
12 See contribution (page 71) by Mrs Brenda Reynolds, mother of Julie [Wenn], a survivor of cisplatinum 
treatment for ovarian and lung tumours. 
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Glasgow, most people didn’t know what their diagnosis was, or why they had 
been referred to an oncology unit. That’s only 30 years ago. That changed over 
that period, because you had young men who asked – ‘Tell me about the AFP 
(alpha fetoprotein) results? What’s my scan like?’ – all of this, was important 
for me. It allowed the doors to be opened to a much wider range of patient 
questions. I will perhaps say a little bit more about that later.
Sperm storage, which might not have been thought about but for that group 
of patients, suddenly became relevant, because they were young people, going 
to have quite serious treatment and quality-of-life issues around vomiting – 
and, in case I forget, people used to vomit when they saw me; some of you 
will have noticed this, as they went past a hospital they would just vomit. 
That’s something that Pavlov said some time ago.13 So it is really interesting 
to reflect.
Today, we want your recollections. Most of them will be scientific, but some 
of them, I hope, will be quite personal, about what it was like to be there 
and how things changed; cisplatin’s development, which we will begin with, its 
use in clinical practice, side-effects and other consequences. As I said before, 
when you read that little phrase from Rosenberg’s paper, ‘I just thought, by 
intuition, I might try it’, is a really interesting comment on how we fund and 
develop clinical research work. There are four broad areas today; there are one 
or two people who may start the discussion, but I hope it’s up to you to take it 
further. The four sections are: chemistry and microbiology; oncology, including 
preclinical aspects, right through to treatment; the antiemetic side of things; 
and there’s a catchall at the end which is called ‘broader aspects’, which is partly 
about some of the issues that I mentioned – the change in the communication 
with individual patients, how that made a much bigger difference to a wider 
group of patients. I am going to ask Andrew Thomson to say a little bit about 
the beginning.
professor andrew Thomson: I am an inorganic chemist by background. I am 
currently at the University of East Anglia (UEA) in the School of Chemical 
Sciences and Pharmacy, and I am told that the origin of this meeting was a 
consequence of the visit by Dr Mark Walport to the University of East Anglia 
a couple of years ago. It was my pleasure and duty to show him some of the 
science going on, and he had done quite a lot of his homework, because he said 
to me, ‘I understand you were involved in the early chemistry of cisplatin’, and 
so we fell to talking about this topic. When he came back to the Wellcome Trust 
13 On the conditioned reflex, see Pavlov (1927). 
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he then suggested that this might form a suitable topic for the Witness Seminar 
series.14 So it is a great pleasure for me to be here today and to see some old faces 
that I haven’t seen for over 30 years. 
I have not worked in this field myself for the last 20 or so years, but I was in the 
laboratory of Barney Rosenberg between September 1965 and August 1967 as a 
postdoctoral fellow, at the time when it was necessary to unravel some chemistry 
of platinum. I happened to know some platinum chemistry, and the reason for 
that is due to the man sitting over there, Professor R J P (Bob) Williams, from 
the University of Oxford, who is celebrating his eightieth birthday this year, 
I am delighted to tell you. Studying for my DPhil with him at Oxford, I was 
looking at some square planar platinum compounds, studying their colours.15 
In the course of that doctorate, as it came to the end, I began to think about 
postdoctoral work. Bob Williams alerted me to the fact that Barney Rosenberg 
had made an interesting discovery. By putting a couple of platinum electrodes 
into a growth medium of E. coli and passing an AC current he observed after a 
while that they grew in filaments.16 Rosenberg, with his technician Loretta Van 
Camp, was conducting these experiments, to see if they could interfere with 
cell division processes by applying electric fields. Rosenberg was a physicist by 
background, and he was intrigued by the pictures of mitotic spindles when 
cells divide. The fact that E. coli had no mitotic spindles did not inhibit him 
from trying this experiment. They quickly discovered that the alternating 
electric current caused some platinum to dissolve from the electrodes. A series 
of remarkable observations made by his technician, Loretta Van Camp, who 
unfortunately is not here, followed, and she soon showed that it was nothing 
to do with the electric field per se. She tested a number of platinum salts. There 
are two things you need to know about platinum chemistry: that it has two 
common oxidation states, II and IV, and each oxidation state dictates a different 
stereochemistry on a surrounding group of ligands. In the platinum (IV) state 
it forms a six-coordinate octahedral complex [Figure 1]. 
On your chairs, you will find a handout, which is in fact the handout I give 
to third-year undergraduates at UEA when I give these lectures.17 I am not 
14 See pages xiii–xv.
15 Day et al. (1965a and b).
16 Rosenberg et al. (1965).
17 The handout will be deposited with the tapes, correspondence and records of this meeting in Archives and 
Manuscripts, Wellcome Library, London.
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going to go through it all, of course, but there are some pictures there that you 
might find of interest. In Figure 2 you will see a picture of a platinum (IV) 
complex, which is an octahedral complex; it binds to six groups. It dictates 
that stereochemistry on the surrounding ligands. But the lower oxidation state, 
platinum (II), superimposes a square planar geometry on four ligands.18 The salt 
used was [PtCl6]
2-, a platinum (IV) complex. This compound loses its ligands in 
response to light, the process of photo-ejection. 
When Rosenberg and Van Camp first tested [PtCl6]
2-, the only platinum 
compound available on the laboratory shelf, it seemed to kill all the E. coli cells. 
But if you leave the culture in the light, then slowly the platinum is transformed 
into a form that then forces filamentous growth of E. coli cells. 
What was that photochemical process? What was the active ingredient that 
was giving rise to filamentous growth? That was the chemistry that I studied in 
Rosenberg’s lab with a graduate student called Eugene Grimley. We did curtain 
electrophoresis19 to separate by charge, and it became clear to us that the chemical 
species that was causing filamentous growth of E. coli was a neutral species of 
platinum (IV).20 Figure 2 shows the best answer we could come to, namely, that 
the active product was platinum (IV) with four chloride ions around it and 
two ammonias. Rosenberg was a physicist and I said to him, ‘Well, of course 
that species has two stereoisomers, cis and trans’. ‘What are stereoisomers?’, was 
Barney’s reply.21 I remember standing at his blackboard and giving him a tutorial 
on the chemistry of platinum. So it was clear that I had to synthesize both the 
cis and trans isomers and test them to see whether the two stereoisomers had 
different biological effects.
18 Note that cisplatin consists of a central platinum atom surrounded by four ligands: two ammonias and 
two chlorides. A high antitumour activity results when the two chloride ligands are bi-aquated in aqueous 
physiological environments; cisplatin can then react directly with DNA and display cytotoxic activity.
19 Professor Andrew Thomson wrote: ‘Curtain electrophoresis is the process where a mixture of analytes 
is flowed under gravity, in a suitable solvent, down a vertical sheet of absorbent chromatography paper, 
while a high DC electric field is applied across the sheet horizontally so that oppositely charged species are 
deflected to the right and left, whereas a neutral analyte flows vertically down the sheet. The analytes are 
thus fractionated according to charge across the width of the paper and each can be collected in tubes held 
below the paper.’ Letter to Dr Daphne Christie, 18 February 2007.
20 Rosenberg et al. (1967a).
21 Professor Andrew Thomson wrote: ‘Rosenberg is known as “Barney”.’ Note on draft transcript, 
18 February 2007.
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The synthesis was first done in 1844 by Peyrone.22 The synthesis of the platinum 
(IV) cis and trans goes via the platinum (II) oxidation state [Figure 3]. 
Platinum (II) is very remarkable. It dictates a square planar stereochemistry and 
the ligands do not exchange very fast. I will come back to this point. So the 
synthetic route enables one to make both the cis and trans platinum (II) isomers, 
which you can oxidize to the platinum (IV) state. 
So that was the chemistry I carried out in the Rosenberg laboratory. It was 
nineteenth-century chemistry, it wasn’t new, but I happened to know where 
to find it, being an inorganic chemist. If you have a compound, then you can 
test it. And so we tested the platinum (II) isomers for filamentous growth, as 
well as the platinum (IV) isomers. It was clear that the cis platinum (II) was 
much more effective at forcing filamentous growth than anything else. The cis 
platinum (IV) isomer was also effective.23 That work was reported in the Journal 
of Biological Chemistry in 1967, by myself and Rosenberg and Grimley.24 
22 Professor Andrew Thomson wrote: ‘Cis-Pt(II)NH3)2Cl2, cis-platin, was first synthesized by M Peyrone in 
1844 [Peyrone (1844)] and has been called Peyrone’s chloride [cis-dichlorodiammineplatinum (II), or its 
higher oxidation state equivalent, cis-tetrachloro-diammineplatinum (IV)]. Its structure was first elucidated 
by Alfred Werner in 1893.’ Letter to Dr Daphne Christie, 20 August 2006. See Figure 3. Professor Alfred 
Werner (1866–1919) won the Nobel Prize in Chemistry in 1913 for proposing the octahedral configuration 
of transition metal complexes. See http://nobelprize.org/nobel_prizes/chemistry/laureates/1913/werner-
bio.html (visited 28 March 2007).
23 Professor Andrew Thomson wrote: ‘In the Rosenberg laboratory in October 1966, as recorded in his 
lab notebook, A J Thomson synthesized, by standard methods, the four compounds, cis- and trans- Pt(II)
(NH3)2Cl2 and cis- and trans- Pt(IV)(NH3)4Cl2. On 2 November 1966, these samples were used by L Van 
Camp to test which of them was capable of forcing filamentous growth of E. coli. The cis-, not the trans-, 
isomer of Pt(IV)(NH3)4Cl2 was effective in causing filamentous growth. However, the cis-, but not the 
trans-, isomer of Pt(II)(NH3)2Cl2 was even more effective at inducing filaments in E. coli. For this reason 
further testing of biological efficacy focused almost exclusively on cis-Pt(II)(NH3)2Cl2 rather than the cis-
Pt(IV) complex. The initial testing of antitumour activity against sarcoma 180 in mice and on L1210 
leukaemia cells in tissue culture by the National Cancer Institute (NCI), Washington, was carried out on 
the sample of cis-Pt(II)(NH3)2Cl2 synthesized by A J Thomson. Hence, it was the need to synthesize cis-
Pt(II)(NH3)2Cl2 as an intermediate in the synthesis of cis-Pt(II)(NH3)4Cl2 that gave rise to the idea by A J 
Thomson to test cis-Pt(II)(NH3)2Cl2 (cis-platin). See Cancer Under Siege [Goodfield (1975): 139–66]. June 
Goodfield attended the Second International Symposium on Platinum Coordination Complexes in Cancer 
Chemotherapy, in Oxford in April 1973. She quoted Barnett Rosenberg as follows: “Andy (Thomson) was 
the first to synthesize the drug (cis-platin) and confirm its structure in relation to its antitumour activity. He 
is the true discoverer and is entitled to establish the name for the whole field”.’ Excerpt from a letter to Dr 
Daphne Christie, 20 August 2006. See also Connors (1973); Connors and Roberts (1974).
24 Rosenberg et al. (1967a).
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Figure 2: Metal dissolves from the platinum electrodes under the influence of an AC electric 




 to yield [Pt(IV)Cl6]
2-
. Under the influence of light, 
ligand exchange occurs to yield a mixture of cis and trans isomers. The cis isomer causes 
filamentous growth in E. coli whereas the trans isomer does not. [Pt(IV)Cl6]
2-
 is inhibitory to 
cell growth. 
Legend provided by Professor Andrew Thomson.
Octahedral six-coordinate platinum (IV) complexes.
Figure 1: Platinum (II) (top) and platinum (IV) ions (bottom) dictate different coordination 
numbers and geometries on a set of surrounding ligands. 
Legend provided by Professor Andrew Thomson.
Planar four-coordinate platinum (II) complexes.
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Figure 3: Synthesis of cis and trans isomers of diamminodichloro Pt (II). 
Figure 4: Chemical properties of cis-platin relevant to drug action. It is a bifunctional reagent since 
the pair of cis chloride ions are labile to nucleophilic substitution whereas the pair of cis ammine 
groups remain inert to substitution. The di-chloro form is maintained by a high Cl- concentration 
as a neutral complex that will cross cell membranes but inside the cell, in a lower chloride medium, 
will become labile undergoing hydrolysis. 
Legend provided by Professor Andrew Thomson.
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Figure 5: Binding modes to DNA of platinating and alkylating agents. Cis-platin cross links via N7 of 
guanine bases on the same strand of DNA. Sulphur mustard cross links DNA strands by reaction 
with the N7 of guanine bases on opposite strands. 
Legend provided by Professor Andrew Thomson.
Figure 6: Structures of some second generation platinum drugs. 
Left. Carboplatin (JM8) cis-diammine (1,1-cyclobutane-dicarboxylato) platinum (II). Right. Iproplatin (JM9)  
cis-dichlorobis (isopropylamine) trans-dihydroxyplatinum (IV).
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So we knew that there was this very interesting stereochemical difference, with 
quite different biological properties of the cis and the trans forms.25 So what is the 
significant chemistry of the cis isomer? Bob Williams was much involved in these 
discussions, of course, at that time.26 The cisplatinum (II) isomer will exchange 
two of its ligands; the two chloride ions will exchange rather rapidly [Figure 4]. If 
you put it into water with no chloride, the water will displace the chloride ions. 
If you raise the chloride ion concentration again, then the chloride ions will be 
taken up and will reform the cis complex. Hydrolysis occurs with a half-life of 
about six hours. But the amines do not exchange for many, many weeks. 
This remarkable chemistry of platinum ensures that some of the ligands will 
exchange within a matter of hours, and some are so kinetically inert that they 
cannot be exchanged over months. In that sense platinum (II) chemistry has 
some analogies with carbon chemistry. So this was really a bifunctional reagent 
that we had discovered, with two leaving groups on the cis side, on the same 
side, of the molecule. The amines were kinetically inert. It was also a neutral 
complex, so we guessed that it could pass across membranes and into cells. 
At that time, one area of interest was in classical alkylating agents, and the 
differences between the so-called ‘bifunctional’ and ‘monofunctional’ 
alkylating agents, and if you look at a picture of a famous sulphur mustard 
[Figure 5], which, of course, is the classical bifunctional alkylating agent. We 
had a bifunctional agent. But the question was, ‘What was its target?’ I will 
come back to that point in a moment.
While we were looking at targets, Rosenberg had the notion that if we had an 
agent which inhibited cell division in E. coli and could cause filamentation, 
perhaps it would kill higher cells. I am not sure whether Barney knew this or 
not – Bob Williams may speak to this point – but certainly it was known by 
microbiologists that there was a correlation between those agents that cause 
filamentation and can induce lysis in lysogenic bacteria, and some of the 
functionality of classical alkylating agents.27 But I am not sure that Barney knew 
that. Nevertheless, he brought in half a dozen mice carrying sarcoma 180, I 
made the compounds, and Loretta Van Camp injected them into the mice. You 
can imagine the jokes in the lab. Only in the USA would you inject platinum 
25 See Connors et al. (1972); Cleare and Hoeschele (1973a).
26 Thomson et al. (1972).
27 Loveless (1966).
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into an animal.28 Within eight days there was regression from the cis but not the 
trans isomers. That work was published in Nature in 1969.29 Once that paper 
had appeared in Nature, then the UK scene became very active. The reason 
for that – and I shall stand corrected, perhaps, by Eve Wiltshaw – was that 
Alexander Haddow, who was Director of the Chester Beatty at the time, picked 
up that paper. The reason he said that he picked it up was because Haddow had 
consulted on nickel carcinogenesis in the South Wales metallurgical industry and 
he knew enough inorganic chemistry to know that platinum and nickel were 
in the same group in the periodic table. There was a paradox called ‘Haddow’s 
paradox’, which said that all things that cause cancer will also cure cancer,30 
which presumably was a statement about attacking DNA, whether you mutate 
it, or whether you kill it. So Haddow thought maybe the fact that platinum 
would appear to cure cancer, and nickel would cause it, was another example 
of ‘Haddow’s paradox’. Once Haddow had picked this up it, of course, meant 
that the whole power of the Chester Beatty Research Institute then became 
very interested in this problem.31 It led to the setting up of a group of people 
in the early 1970s in the UK, which was funded by a man called Ken Maxwell, 
from Rustenburg Platinum Mines, and also by Johnson Matthey.32 It was a very 
interesting group. It consisted of clinicians: Eve Wiltshaw was part of that in 
the early 1970s, Tom Connors was the pharmacologist; he is no longer with 
us.33 There was an inorganic chemist from UCL called Martin Tobe making 
new platinum compounds, and Mike Cleare from Johnson Matthey.34 I was 
studying molecular mechanisms, and John Roberts started to look at DNA 
repair mechanisms.35 That group worked together in the UK for a number of 
years with funding from Rustenburg Platinum Mines. The work of that group 
meant that the clinical work, I think, went much more rapidly. In the USA it 
28 Professor Andrew Thomson wrote: ‘This was in reference to the extravagance (by the then UK standards) 
of research budgets at that time in the USA.’ Note on draft transcript, 1 April 2007.
29 Rosenberg et al. (1969).
30 According to Haddow’s paradox, anticancer agents may also be carcinogenic. See Haddow et al. (1948); 
Reslová-Vasilukova and Williams (1979): 28. 
31 Haddow (1961); Jeney and Lapis (1985). 
32 Mr Ken Maxwell was Managing Director of Rustenburg Platinum Mines Limited, South Africa.
33 Professor Thomas A Connors died on 4 February 2002. See Double (2002). 
34 For biographical note see page 99.
35 Roberts and Thomson (1979); Roberts (1980); Brookes and Venitt (1991). 
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didn’t go quite as fast. There progress was dependent on the NCI (National 
Cancer Institute), but the influence of the Chester Beatty here, working in that 
group, pushed the clinical work forward extremely rapidly. Perhaps I should 
stop there. That is my recollection of how it all got going.
calman: What a wonderful tutorial on chemistry and the beginnings of this 
debate, and I hope that others will have their personal recollections of that time. 
But maybe I should ask whether you, Professor Williams, would like to say 
something at this stage in terms of your own background, since you have been 
referred to so often in this?
professor robert [Bob] Williams: I started research as a young man in 1948 
with a deep interest, gathered at school, in the way metal ions may interact 
with any living system, and I have worked on that for the whole of my life. My 
last book is published now – it is the last piece of work I will do – called The 
Chemistry of Evolution.36 The chemistry of evolution, according to me, is totally 
dependent on metal ions. You may not want to believe that, you may think it 
is totally dependent on DNA, but I believe that’s a thundering mistake. Let me 
start then with my own career, which was biased by school education towards 
physics, chemistry and mathematics. You have to remember that in those days 
in education, if you went to the kind of school I did, a boys’ grammar school,37 
you were not allowed to touch biology, because biology was for girls, just like 
that, and if you said you wanted to do biology, they would say to you that you 
must be stupid because all doctors are stupid and so are all vets, and so it’s only 
stupid people who do medicine – there is no system whatsoever in biological 
sciences. So we were drilled and when I went to the University of Oxford, 
it was exactly the same. I said to the first tutor I met there that I wanted to 
study biology at the same time that I studied chemistry, and he replied, ‘Oh, 
don’t bother to do that, you can learn all of biology later’. That was the total 
attitude to education in biological sciences. Despite these attitudes, my mind 
was made up – I wished to study metal ions in biological systems. Now this is 
all relevant – since I was well-trained in physical sciences by 1950 but had read 
a good deal on biological sciences for myself. What happened next in this story? 
Andy has introduced some parts of it very nicely but didn’t explain how I met 
Barney Rosenberg. 
36 Williams and Fraústo da Silva (2006).
37 Wallasey Grammar School, Wallasey.
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Because of my interest in metal ions in biology, I thought that there must be 
a way electrons passed through biological materials using these ions. If you 
read the literature between 1950 and 1970, there’s intense general interest by 
biophysicists in the way in which electrons pass through biomaterials. There 
were people, including famous names like Szent-Györgyi, who always thought 
that cancer was somehow related to this problem. In fact, there was a Ciba 
Foundation Symposium on this subject, where I was the Chairman, which is 
dedicated to Szent-Györgyi.38 I remember that I got up and said that I thought 
what Szent-Györgyi was saying and thinking was nonsense. Well, that didn’t go 
down very well, as I was supposed to be the Chairman of the whole meeting and 
I said that at the very beginning. So, having cleared the air, we started to fight, 
and it was very interesting and good fun, from which I learnt a great deal. 
Going back to my meeting with Barney Rosenberg, I had developed these 
interests in electron transfer properties before 1960, and so had Barney. My 
work by 1961 led to the proposal of how bioenergetics work through electron 
and proton transfer.39 I didn’t invent chemiosmosis, I won’t claim that, that’s 
due later to Peter Mitchell,40 but I proposed that bioenergization goes through 
electron and proton gradients. So when there were meetings in the USA on the 
bio-electrochemistry of protons and electrons to which I was invited, and so was 
Barney, who had similar interests, I went to one of those meetings in California, 
where Barney Rosenberg was present.41 Barney was a biophysicist and you could 
call me by then, a biochemist. When we met we obviously had a common 
interest in electron conduction in proteins, and the results of his attitudes 
were, I think, that platinum is the only drug that will ever be discovered by a 
biophysicist. The way he came to it is very strange.42 Because he believed that 
electrons or electricity affected bacterial growth – Andrew has described the way 
he looked at this probability43 – he designed his experiments of passing current 
through a bacterial cell suspension using platinum electrodes. He didn’t think 
the consequences had anything to do with chemistry, because he knew very 
little chemistry. He was a physicist. And that’s why he called on me. He found 
38 Wolstenholme et al. (eds) (1979).
39 Williams (1961, 1974, 1989). 
40 See Mitchell (1970, 1977).
41 Williams (1964).
42 See page 3, notes 4 and 5. 
43 See pages 6–15. 
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out from somebody, and I didn’t know who it was, that it was the platinum that 
dissolved in the water from the electrodes that was causing the observed changes 
in the bacterial cells: it was not the electrode fields. Barney phoned me up and 
said that he had seen that I had done something on platinum chemistry.44 This 
work was published with Andrew earlier and was pure physical chemistry. 
By the way, I should say I did experiments all the time in chemistry – to try 
to model what was happening in biology – but I did not necessarily tell my 
pupils the reason why they were doing the experiments, simply because I 
thought they would have been totally lost. They were so trained in chemistry 
that they wouldn’t have seen how I could move over from their subject into the 
biological sciences. 
To continue: Barney rang me up and said, ‘Bob, I am in difficulty, I don’t 
understand much about platinum chemistry. Will you be my consultant?’ I said, 
‘No, I can’t work as a consultant with somebody 5000 miles away, we will just 
get into a terrible jumble, but what I will do is find a pupil of mine, who is well 
versed in chemistry, who can come to work with you’. I knew he had to be an 
adaptable and a very good scientist. I told Barney that he will come one bright 
day and help you. I didn’t have a man in mind at that time, until Andy came to 
work with me and had worked on platinum chemistry. The reason we worked on 
platinum I needn’t go into, it’s all to do purely with how to do a certain form of 
spectroscopy.45 At the same time my group also looked at certain electron transfer 
systems so that Andrew became knowledgeable in this topic too.
Now, you know that careers are funny things. I was then tutoring chemistry 
mainly. In the middle of 1966 though, which was just a little later than this, I 
went across to Harvard University for a year, determined to get out of chemistry 
and to find a university which would allow me to do biology. So I worked in 
the Peter Bent Brigham Hospital [Boston, MA] at Harvard with Professor Bert 
Vallee46 and learnt some chemistry, biology and metal chemistry in proteins. 
This helped me a very great deal I have to say, learning biology there. I came 
back to Oxford in 1967 and said to my colleagues: I am not going to teach any 
of this chemistry stuff any more, I am teaching biochemistry or nothing. So I 
44 Day et al. (1965a).
45 Professor Robert Williams wrote: ‘We wished to understand polarized transitions using new equipment.’ 
Letter to Dr Daphne Christie, 27 January 2007.
46 Professor Bert Vallee, Professor of Biochemical and Biophysical Sciences and Medicine, Harvard 
University, Boston, MA, USA. 
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asked, ‘Can I come back on those terms’? They said, ‘OK, you can come back 
but your salary is reduced’. 
This period in Harvard helped us in thinking about platinum. Later on, 
because interest in metal ions began to grow, and partly perhaps because of 
these platinum drugs, I was made a Napier Royal Society Research Professor in 
1974, and the strange thing is that the fund money was left by Napier, who had 
died of cancer.47 Napier had left money to the Royal Society and initially it had 
been given to cancer research. They were very disappointed with the results of 
that, because, of course, one man on his own, doing cancer research, was clearly 
a complete waste of effort; you had to have a big organization or team. What 
happened then was, very simply, that they got hold of me and said, ‘Look, there 
are loads of diseases we don’t understand. Will you investigate them, that is 
investigate in a general sort of way, the causes of diseases of an unknown cause?’ 
So that was my brief from the Royal Society, and I loved that brief. I have 
worked on it for 20 years, often on different types of drugs, but platinum has 
been but one of great interest.
I would like to say one or two other things about Rosenberg, and a couple of 
other people who have been involved, who have not necessarily been mentioned 
sufficiently by Andy, but it is obvious that you can’t include everyone. Rosenberg 
did learn some biology, but basically he was often, shall we say, wild in his 
thinking, perhaps very imaginative is a better way to put it. I think all who 
knew Barney then will agree with that. Much of what he proposed you did 
not believe and you had to go away and ask, ‘Was it possible?’ For example, he 
believed, somehow or other, that platinum was affecting the immune system. 
He didn’t think it was anything necessarily to do with DNA at first, and we used 
to argue about this. Here he had a piece of luck, he employed various Czech 
scientists, and it’s a pity one of them couldn’t be here to represent their work: 
Gerry Droknik and a young woman called Scarlett Reslová, his pupil. She was 
called Scarlett after the well-known Scarlett in Gone with the Wind by her father, 
who had, I believe, been an airforce pilot in the war and seen the film.48 She 
discovered a very interesting possibility concerning the action of cisplatinum. 
She had done microbiology, and this is where, as so often, microbiology comes 
47 The Napier Research Professorship is for research with the object of ascertaining the cause of cancer, 
including any corresponding allied disease and the means of prevention, cure and alleviation. See 
www.admin.cam.ac.uk/reporter/1999-2000/weekly/5819/58.html (visited 26 April 2007).
48 Gone with the Wind by Margaret Mitchell, published in 1936, won the Pulitzer Prize in 1937 and was 
filmed in 1939 with Vivien Leigh as Scarlett O’Hara.
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into cell studies. She had seen that if she treated with platinum, E. coli cells that 
had inserted phage, then the phage was liberated. She immediately concluded 
that platinum acted by an attack on DNA. That led to a big argument between 
her and Rosenberg, and in the end she published her work on her own, possibly 
because he didn’t think she was right. It’s a very short paper, and it was actually a 
very fine paper.49 The result of that was twofold – I am sorry to go on a little bit, 
but there are some very amusing aspects of all this. Several Czechs went back 
to Czechoslovakia – she was one of them – just at the time when the Dubcek 
era collapsed.50 I had been very, very foolish; I had told her from the USA to go 
back. I said, ‘You have to go back to your own country, somebody has to look 
after the place’, but I had never been in an occupied country. So I went there 
repeatedly, about four times, between 1968–75, carrying platinum compounds 
that were to be tested in Czechoslovakia, mostly in microbiological assays. I 
won’t go on about that, but as a consequence, Reslová, myself and Andy wrote 
a long review in 1972,51 and in that review we suggested quite a number of the 
possible platinum-complex variants which you could work with, including the 
oxalate, I think that is right. I did very few additional experiments, but I do 
want to say one thing about the Americans.
The Americans were scared stiff of this drug; they would not let it be tested in 
any hospital under NIH control. The result was that Barney could not even 
run an open meeting in the USA on the drug, so he appealed to me to run one 
in Oxford. The first open [international] platinum meeting was run in Oxford 
in 1973, and basically I organized it at Wadham College and in the inorganic 
chemistry laboratory, which is totally appropriate, as cisplatin is inorganic.52 
Almost all previous drugs were to do with organic chemistry. One outcome was 
that NIH were furious and sent a man across to lecture us on why this drug 
was completely unsuitable and would be poisonous and therefore would not be 
effective in any circumstances. Of course there was a big risk, there’s no doubt 
about that, and I later investigated a little bit about platinum protein chemistry 
49 Reslová (1971/2); Thomson et al. (1972).
50 See, for example, Golan (1973).
51 Thomson et al. (1972). Professor Robert Williams wrote: ‘Dr Scarlett Reslová on return to Prague 
worked mainly in microbiology. She was very resistant to the authorities until Havel came to power. For a 
short while she was a high-up adviser to his government and wrote a brief note in Nature concerning the 
future of science in Czechoslovakia. She became unwell and is now semi-retired.’ Note on draft transcript 
4 April 2007.
52 See note 23.
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with the biophysicists and other people in Oxford. Platinum does attack a great 
variety of biological polymers. There are small things I can add, but I want to get 
across that this was a very strange and fortuitous development. There could not 
be anything more like a series of steps, which one could only call good luck, plus 
Barney’s determination and belief. Everything could have gone wrong at almost 
every step, when the work could have been stopped entirely. One item, I think, 
that Andy didn’t remember is the name of L Woff. He was a microbiologist, a 
French Nobel Prize winner, who in fact knew about filamentous growth and 
phage release from bacteria.53 He did not say anything specifically, but just 
that sometimes there’s a correlation between cancers and filamentous growth. 
He rather pushed that on one side. Remember, this assumption was central to 
Barney’s thinking. He [Woff ] did say that anything that releases phage from 
bacteria is much more likely to be an anticancer agent, and that’s where Reslová, 
who was a microbiologist, got her lead.54 But the start of platinum drugs is really 
a biophysics study, which is a very strange starting place. That is my view of the 
history, but I may interrupt later, with various bits and pieces I know about. 
calman: It really is fascinating. Just in the first two comments from Andrew 
Thomson and Professor Williams, you can begin to see how this started. 
Dr James hoeschele: I want to add a few facts. I overlapped with Andrew 
at MSU – actually I preceded him. I was a graduate student at MSU from 
1959 to 1965. I knew of Dr Rosenberg, but wasn’t working for him at that 
time. I was working as a graduate student in the chemistry department doing 
electron transfer reaction studies. But Dr Tom (Thomas) Krigas, whose name 
has not been mentioned so far, and who had a role in the platinum project, was 
hired by Dr Rosenberg while a chemistry graduate student to do some synthetic 
work making some platinum chloroam(m)ine compounds. He was earning his 
keep, basically, doing this. And so he would come to my laboratory off and on, 
and we talked about the whole process (the potential role of platinum in the 
filamentation of bacteria), back in 1963 and/or 1964. We talked specifically 
about what might be causing this effect, and it was mentioned during our 
discussion that it was possibly the electrolysis. Now that seemed a little far-
fetched at the time, because my understanding of electrolysis was in the context 
of DC electrolysis and not AC electrolysis. But it was only under AC electrolysis 
 
53 Professor Robert Williams wrote: ‘L Woff worked in the period before and after the Second World War.’ 
Note on draft transcript 4 April 2007.
54 See, for example, Reslová (1971/2); Harder (1974): 98–112.
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that the filamentation occurred. It happens only when the frequency ranges 
between something like 5000–10 000 cycles per second. 
So then I joined the Rosenberg group as his first postdoc student in February 
of 1970, having left and then returned to Michigan State University. Barney 
[Rosenberg] was interested in me because I had radiochemical experience: 
radiochemical experience to radiolabel cis- and trans- platinum and other 
compounds that we did, in studying the uptake, distribution, and retention 
of platinum in mice. And along with the distribution studies, Mike Cleare 
joined the group in mid-1970, and he and I laid out a programme of synthesis 
of cisplatin analogues. Mike had much more prior experience in coordination 
chemistry than I did, but together we designed (based on earlier work) a whole 
programme of synthesis in which you could vary the metal, and both neutral and 
anionic ligands. And we divided up this work and set about to find out what the 
structure–activity relationships were. Mike was fresh out of graduate school in 
England, and working with Johnson Matthey, but on loan to Barney Rosenberg. 
So that was my involvement. While I was there, the very first platinum meeting 
was held not in Oxford but at Michigan State. It was in 1971. I think you were 
there, Bob [Williams]. Were you, Andy [Thomson], there as well?55 It was a small 
group. It included John Venditti from the NCI, Sir Alexander Haddow and Peter 
Brookes from the Chester Beatty Research Institute in England, and others. John 
Roberts was also there, I believe. And that was the start of the collaboration with 
Europe, at least as I knew it, at that point. 
One very personal incident that I had, and want to share with you, is that Mike 
Cleare and I took Sir Alexander Haddow (and his wife) to an American football 
game. Now he was blind, as most of you probably know, but we took him to a 
MSU football game. He sat right in the very front row of the upper deck and I 
never saw anyone enjoy a football game as much as he did. It was a really rare 
experience – he was a wonderful man. 
calman: Thanks very much. Before we move on to Ken Harrap, are there any 
other contributions on that very early period, defining the first meeting on 
cisplatinum; it is now 1971. Any other comments on the early chemistry?
Williams: I wonder if Tom Connors’ name ought to be mentioned again, 
because he was very forward in helping in the involvement of the MRC, I think. 
 
55 Professor Andrew Thomson wrote: ‘Andy Thomson attended, Bob Williams did not.’ Note on draft 
transcript, 18 February 2007.
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I think he was from the Chester Beatty and was the one who often remembered 
Haddow’s work.56 
calman: I am sure Ken Harrap will pick that up. It brings back enormously 
happy memories for me at the Chester Beatty with Tom [Connors] and Ken 
[Harrap] and others at the time.
professor kenneth harrap: It’s very difficult to distinguish them, everyone at 
the Chester Beatty was mad; you didn’t get a job there unless you were mad. But 
it was from the early work [From the floor: Would it be Tony Loveless?] Thank 
you, that’s his name.57
calman: Any other comments from that early period of inorganic chemistry of 
platinum, early meetings, reflections of Rosenberg et al.?
Williams: On the bacterial filamentous growth, if you read the literature you 
will find that if you treat Escherichia coli with excess magnesium in the water, 
you will get filamentous growth of E. coli. You don’t [only] need platinum.58
calman: Perhaps I could ask Ken Harrap, who was at the Chester Beatty, to 
speak. He and I met in 1972; it seems like a long time ago, but he looks just 
the same.
harrap: At the time that we are talking of, or just before, Tom Connors and I did 
our PhDs at the Chester Beatty Research Institute, as it was called then, in the 
Fulham Road, London, and we were both in the chemistry department.59 My 
supervisor was Professor Franz Bergel, and I was doing biochemical-type things 
with enzymes and Tom Connors was doing pharmacological-type things with 
alkylating agents, which was the major interest of the Chester Beatty Institute. 
There was a huge investment in alkylating drugs and, in fact, you are probably 
aware that many of the compounds that were first produced in the chemistry 
department there are still available for regular use: myeleran, melphalan, 
chlorambucil. Eve Wiltshaw – who is fortunately here – was involved in the 
clinical evaluation of these early alkylating drugs. I remember the time that 
you mentioned, when Alex Haddow came back from this particular meeting 
56 Professor Tom Connors is mentioned earlier, see page 14, note 33. See also pages 99–100.
57 See page 13, note 27.
58 Rosenberg et al. (1967a and b); Lusk et al. (1967).
59 The Chester Beatty Research Institute – Institute of Cancer Research, Royal Cancer Hospital. See Royal 
Cancer Hospital, London (1951). See also Haddow (1961); Brunning and Dukes (1965).
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in Barney Rosenberg’s lab and summoned Tom and, I think, he summoned 
you as well, Eve, didn’t he at one stage? And he said, ‘Look, there is all this 
platinum stuff going on in the USA, it is really very exciting, they are showing 
activity in animals, but this drug is so terribly toxic that the US FDA (Food 
and Drug Administration) won’t allow them to run a clinical study. Well, that’s 
nonsense, we can do this here’. So Tom Connors started a collaboration with 
JM, that’s already been mentioned, particularly with Mike Cleare, and he and 
Mike Cleare and other chemists at JM started looking at analogues, looking for 
a drug which might perhaps be more potent than cisplatin, so that you could 
use less of it, and perhaps get less toxicity. On the other hand, Eve Wiltshaw 
and her group pursued the first Phase 1 study of cisplatin and I do hope we 
are going to hear something about the clinical work fairly soon, because this is 
what has driven everything that has happened since, it really is. It is the toxicity 
of cisplatin, allied to its extremely potent antitumour activity in the clinic, that 
has driven everything that has happened subsequently.60 So where I came into 
the picture was after Tom had left to become Director at the MRC Toxicology 
Unit at Carshalton, Tom’s people were allocated to me and I became much more 
interested in pharmacology than biochemistry, and ergo, there was an interest 
in platinum with that, and we started trying to look for a less toxic analogue, 
but equiactive cisplatin. On the way we came across carboplatin, JM8 [cis-
diammine (1,1-cyclobutanedicarboxylato) platinum (II)], Paraplatin® [Figure 
6], which proved to be a good candidate. 
Hilary Calvert was responsible for the clinical study in the Marsden of 
carboplatin, and made some extremely forward-looking observations on the 
clinical pharmacology of that compound; I will leave him to tell you about 
that.61 Subsequently, we discovered other analogues, and I should emphasize 
that the JM connection was paramount here; it was paramount in all of Tom’s 
work, and in my work, because we had no platinum chemistry in the Institute.62 
All the chemistry was done at JM, and this had always been a chemistry-driven 
programme. It’s been a delight to work with JM. As we learnt a little more about 
platinum, it became clear that there were limitations in carboplatin. Incidentally, 
I notice Andy Thomson’s handout says that carboplatin is active in resistant 
tumours but, in fact, there is extremely slender evidence for that. So what we 
60 Wiltshaw and Carr (1974).
61 See page 27 and Calvert et al. (1989); van Warmerdam et al. (1995); for a review see Kelland (1993).
62 Professor Andrew Thomson wrote: ‘Many analogues were also synthesized in the laboratory of the late 
Professor Martin Tobe, in Chemistry at University College, London.’ Note on proofs, 7 August 2007.
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started to do was to look for compounds that might be active in platinum-
resistant tumours, and we came up with one which is still in clinical development; 
it is now called picoplatin, AMD473 [cis-amminedichloro (2-methylpyridine) 
platinum]. Our second compound, JM216, cis-, trans-[PtCl2(O2CCH3)2(NH3) 
(cyclohexylamine), Figure 7], was developed predominantly to produce an oral 
formulation. And JM216 is one such, and is pursuing clinical development, it is 
known as satraplatin. So there is a lot of subsequent development after cisplatin. 
I think we ought to hear a bit about the clinical utility of cisplatin and maybe 
have some comments from the audience on that.
calman: Thanks, Ken, you bring back huge memories for me, because it was 
meeting Tom, you, Hilary and others, on an annual basis – we had a meeting 
at Burnham Beeches, which was good fun – and had us playing rugby in the 
middle of the bar for large periods of the evening. Clearly there was also some 
exchange of clinical and scientific information. And that for me, and I will 
perhaps say a little bit about this in winding up, many of these things seemed 
to be about people and groups, we knew each other, we already identified that 
quite clearly, and groups keep together and share that kind of information in a 
way that is just astonishing. But you are going to reply?
harrap: Just to say that it was Tom Connors who was responsible for this 
strange athletic phenomenon which always happened after a scientific meeting 
and it was always in the bar when people were very drunk. Hilary has also been 
involved in these tournaments. It is called ‘Jumbo’, rugby football played on 
your hands and knees with a match box as a ball; one team defends one wall and 
the other team defends the opposite wall. It gets very bloody and expensive. 
calman: I am not sure whether Wellcome would allow us to demonstrate 
this evening.
Dr eve Wiltshaw: We have talked about Barney Rosenberg – and I don’t want 
to go into that anymore because I think we have his life history more or less – 
and Alex Haddow. I have learnt quite a lot this afternoon about Alex Haddow’s 
interests in platinum compounds. Because when he came to see us, that is 
David Galton and myself, about testing cisplatin on patients, he didn’t say 
much, except ‘this is another alkylating agent’. We had been testing alkylating 
agents for 20 years, and we were not impressed by another one. He didn’t say 
anything about the special things that he apparently knew about the platinum 
compounds, but he did say this was a new series of drugs and that, because 
there was a metal involved in the chemistry, one might have quite unexpected 
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results, both in terms of toxicity and in terms of efficacy. So, although we were 
not keen, we did start a study in 1971. 
Let me just say what it was like then to do medical oncology. Haddow had 
started with a clinical medical oncology unit in the 1950s. There was no other 
unit in the country, and almost no other unit in the world that was doing clinical 
studies in drugs, and as you can imagine, we were not favoured doctors at the 
time. And, in fact, we were called the ‘death-watch beetles’, because we had to 
go to see people who were dying, and try to treat them with totally ineffective 
drugs. Nitrogen mustard was about the only drug that resulted in any kind of 
improvement. The situation in the 1970s was that we had this tiny medical unit 
that had no staff; there were two doctors, David Galton and myself, or David 
Galton and somebody else.63 There were no junior staff and we relied on David 
Galton’s international reputation to attract fellows from abroad to help us with 
the work, and these people were funded by themselves or by their countries; 
there was no such thing as funding for a clinical fellow for medical oncology. 
Nevertheless, they did come and that was a great help to us. There was no 
senior house officer, there was no registrar, and there was certainly no nurse 
to help you. So we did all our IV therapy and work, blood products and so on 
ourselves. It was impossible to do things in a big way at that time. To consider a 
collaborative trial was impossible. There was no unit to which you could hand 
out helpful hints and ask them to collaborate with us. Again, remember, there 
were no nurse data managers, so it was a slow business. 
The other side of the coin at the time was that there were few restrictions on 
trials: virtually no ethical permission was needed, and the hospital relied on 
the doctors not to do anything that might be considered detrimental to cancer 
patients. Again, all our patients knew the diagnosis in the 1970s. They might 
not have known it when they came to the hospital, but they were told when 
they arrived. We found that when they were asked if they would enter a study, 
often comparing drug A with drug B, very few refused. However, that kind of 
permission given by patients was well below what you would have to do now. 
Patients were not told about all the hazards that might occur.
I don’t want to go back on what has already been said. We are talking about ‘luck’ 
in terms of platinum compounds, and one of the things that we decided was to 
treat patients with ovarian cancer, not because we thought that this was the drug 
for ovarian cancer, but for another reason. One was that I had a small practice 
63 See Christie and Tansey (eds) (2003).
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in ovarian cancer patients. The second was that we knew that this was about 
the only adenocarcinoma that responded, however badly, to alkylating agents: 
chlorambucil, cyclophosphamide and so on. They did have a small response rate, 
and therefore we thought that this might be amenable to the new drug. That 
turned out to be a very appropriate way to go, since I already had experience of 
the natural history of ovarian cancer and the rather pathetic response sometimes 
seen using chlorambucil. The first use of cisplatin was impressive to me, and 
I reported this to the cisplatin group at the Oxford conference in 1972/3.64 
Twenty patients were treated and several showed dramatic regression of tumour 
masses and the disappearance of ascites – this was despite the fact that most were 
seriously ill before having this drug. Indeed, all had had previous treatment – and 
remember that ovarian cancer was at that time treated by pelvic radiotherapy or 
pelvic plus whole abdominal radiotherapy. So the effects on the blood counts 
were more extreme than you would expect with previously untreated patients. 
When we spoke at this meeting in Oxford, there were about six US groups also 
speaking on clinical trials. The only person who also had a positive outlook 
about cisplatin was Higby and his colleagues who had treated testicular cancer 
and had found that it was very responsive to cisplatin, and so it was; although 
it turned out that you had to have a combination of drugs to get real cures.65 As 
far as ovarian cancer was concerned, they were not interested in the USA; they 
thought that cisplatin was far too toxic to be used on a large scale. They had used 
it in head and neck tumours in particular, and among the things that they had 
done with other alkylating agents was to escalate the dose, and they produced 
dreadful renal damage and neurological damage. We were lucky; because people 
vomited so much with cisplatin, we gave them post-cisplatin IV fluids, for the 
vomiting, not for the renal function, and it worked; we hardly ever saw renal 
damage. And so, we were able to continue where others weren’t.
calman: What a remarkable testimony that was, and it shows, I think, two 
things: one, the courage of the oncologists but, just as importantly, the courage 
of the patients to be part of that process. You also mentioned the death-watch 
beetle bit. Sixty per cent of the patients referred to me in Glasgow in the first 
64 Dr Eve Wiltshaw wrote: There was one previous conference on the subject of platinum complexes I think 
in Dallas, Texas but a book was published after Oxford to the participants.’ Letter to Dr Daphne Christie, 
31 January 2007. See Connors and Roberts (1974): 178–182. See also note 23. 
65 Higby et al. (1974).
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six months of my appointment there died within the month without treatment. 
That was the referral practice, which many of us saw in the early 1970s, and 
things changed at just about that time. 
professor hilary calvert: It is nicer to be one of the younger members of the 
audience for a change; it doesn’t happen very often any more. 
When Bob Williams started working on metals in biology, I had just been 
born, but only just. I am really going to talk about carboplatin, but my first 
acquaintance was with cisplatin, and that was in 1974 when I got a job at 
the Marsden, because the interviews were the day before those at the National 
Heart Hospital. I was assigned to be Eve Wiltshaw’s houseman, so she did have a 
houseman by 1974. One of the things that I had to do was to give this platinum 
stuff to a patient with ovarian cancer. I, of course, had been taught that you 
couldn’t treat people with advanced cancer and that the drugs didn’t work and 
that they always died. The patient got very sick and looked a bit peaky, but 
came back about two weeks later without any cancer. That was what converted 
me to spending the rest of my career as a medical oncologist. 
I got a research post with Ken Harrap and worked on the famous methotrexate 
for quite a few years, and eventually became a consultant at the Marsden, with 
the specific job of doing new drug trials, which was the first time they had 
appointed anybody to specialize in new drug trials. And Ken said, ‘Well, we 
have this carboplatin stuff, you had better do that’. And so that was my first 
drug to do a Phase 1 trial with. I had made pretty much no contribution to the 
development up to that point, I think, except for one thing where Ken may be 
able to contradict me, but Ken had done a series of very detailed toxicological 
studies in rats, with about eight different platinum compounds, and two of 
them came up clearly ahead for having reduced toxicity: one was carboplatin 
and one was CHIP or JM9 [iproplatin, cis-dichlorobis(isopropylamine)-trans-
dihydroxyplatinum IV), Figure 6]. There wasn’t much to pick and choose 
between the two. We had one meeting and there was one xenograft that worked, 
so I said, ‘Why don’t we try it on that?’ And we did, and the carboplatin 
worked better. I think that’s what finally tipped us into doing the study 
with carboplatin.66 
I think there were two things that really stand out now on the clinical development 
of carboplatin: one was technical, getting the stuff to work; and the second was 
political, because a lot of people didn’t want us to do it. So, I will start with the 
66 Calvert et al. (1982).
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first. We did the Phase 1 study of carboplatin with what is now, of course, a fairly 
conventional methodology of increasing doses and looking at the toxicity, and 
the chief toxicity was myelosuppression with thrombocytopaenia coming out 
as the major feature. And the other toxicities associated with cisplatin, like the 
renal toxicity, were much less, and the vomiting was less severe. But one thing 
that was quite curious and hard to understand was that there was a great deal 
of difference in the different patients, in the way they tolerated it. So you’d get 
some patients that I could give 500 or 600 mg/m2 to, and they wouldn’t have 
much in the way of toxicity, and others on about 200 mg/m2 would get really 
crashing thrombocytopaenia that would last for a long time and be dangerous. 
And we were thinking about this, and there was at that time a growing interest 
in pharmacokinetics in correlation with the toxicity of anticancer drugs, and in 
particular the idea of ‘systemic exposure’ or the ‘area under the curve’ (AUC) 
was coming in.67 For the chemists it is a pretty easy concept, because it’s just 
the law of mass action, so that the idea is that the effect of a drug – the toxic 
or the therapeutic effect – is proportional to the area under the concentration 
curve or the concentration time. And, of course, for a platinum analogue that 
made sense, because we knew it was reacting with DNA, and presumably the 
bigger the area under the curve, the more DNA adducts you form. It turned out 
that carboplatin had very predictable pharmacokinetics, but was very strongly 
affected by renal function, because it is almost all excreted by the kidneys, and 
it is almost all excreted by glomerular filtration, and glomerular filtration was 
something that we could measure. So we were able to put together a little model, 
and work out in advance what dose of carboplatin we would need to give to 
a patient to get a particular ‘area under the curve’. And with my colleagues, 
including Steve Harland and Herbie Newell, who aren’t here, and Ian Judson 
who is, we treated a bunch of patients with variable renal function and worked 
out a formula that was published, which has subsequently – and nothing to do 
with me – become known as the ‘Calvert formula’.68 It has an unbelievably large 
number of citations, because there are an unbelievably large number of people 
who use carboplatin out there.69 And if I am in Japan at a medical meeting, I am 
67 The total area under the concentration/time curve (AUC). See Seymour (1993): 9–39.
68 The Calvert formula can be used to calculate the carboplatin dose accurately in order to obtain a target 
AUC (area under curve) by using only the GFR (glomerular filtration rate). The formula is: dose (mg) = AUC 
(mg ml
-1
 min) x [GFR (ml/min) + 25 (ml/min)]. See Calvert et al. (1989); van Warmerdam et al. (1995).
69 Professor Hilary Calvert wrote: ‘1038 citations reported by the Web of Knowledge’. Note on draft 
transcript, 30 March 2007.
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quite likely to hear among a lot of stuff that I don’t understand at all, the words 
‘Calvert formula’ appearing from time to time, which is always quite interesting 
and gratifying. When we published the Calvert formula, I felt, ‘Well, this is very 
neat pharmacology, it will get me a paper in the Journal of Clinical Oncology; 
that was about the highest impact I could have hoped for in this field, and then 
probably nobody will take any notice of it, because doctors aren’t interested in 
that sort of thing’. And that’s pretty much exactly what happened for about two 
years. But then the marketing manager for carboplatin in the USA working for 
Bristol-Myers picked up on my paper and gave me a phone call and said, ‘Look, 
we are having real problems with this drug, because the oncologists think it is an 
erratic drug that is hard to use, and occasionally their patients fall apart, and they 
really don’t want to use it and they are sticking with cisplatin and would your 
formula help?’ And I said, ‘Well, it might, but nobody really uses it’. So he said, 
‘Well, we need some marketing’. So he took me on a course and trained me in 
presentation and everything, and I did tours of various medical centres in many 
parts of the world, hundreds of air miles, and over a period of two or three years 
they converted about 20 per cent of people using carboplatin, where a platinum 
drug was indicated, to about 80 per cent, and I think they put their sales up in a 
similar proportion, and from that time carboplatin has been the most commonly 
prescribed platinum analogue, although cisplatin is still used. So, without a bit of 
pharmacokinetics, but also a bit of marketing of science if you like, I don’t think 
the drug would ever have taken off and become the big drug it is.70 
The other curious thing was that from the medical side there was quite a lot of 
opposition to the introduction of carboplatin. People had finally found out how 
to give cisplatin without causing too many dreadful effects: by giving the right 
regimen, hydration, diuresis and the right antiemetic regimes and so on, so that 
you could actually give cisplatin to patients. I think many people felt this was a 
big achievement of medical oncologists, and it was also something the surgeons 
didn’t know how to do, so it made the oncologists feel better than the surgeons. 
And so when somebody [Hilary Calvert] came along and said, ‘Well, if you use 
carboplatin you don’t have to bother with all that stuff ’, the oncologists weren’t 
particularly pleased. 
I think another feature was that the commercial partner, Bristol-Myers, also 
was looking for a second-generation platinum analogue although by this time 
70 Professor Hilary Calvert wrote: ‘It is the standard treatment for ovarian cancer and, combined with 
paclitaxel, it is the most popular treatment for non-small cell lung cancer. It is generic, but Bristol-Myers 
Squibb report sales of $246 million in 2003.’ Note on draft transcript, 30 March 2007.
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cisplatin was doing very well. Their favoured second-generation analogue was 
one that had been developed in Holland, called TNO-6 [1,1-diaminomethyl 
cyclohexane sulphato platinum II].71 I think the Dutch had got ahead of the 
English in setting up well-recognized, internationally-recognized, Phase 1 drug 
evaluation centres, and I was pretty much unknown and there weren’t really 
any other people doing it in the UK. So there tended to be more plausibility 
towards the Dutch data. And early on the drug material was provided by JM. 
We formulated some of it ourselves. I was, frankly, rather discouraged from 
continuing with the trials. There were also quite serious supply problems, 
because although JM had made enough, Bristol-Myers after a while, volunteered 
to formulate it, but then it had some problem with its formulation plant and we 
didn’t have the raw material, and we didn’t have the formulated product back, 
and we were only able to continue by two routes: one was by acquiring some 
more material and formulating it in the Marsden itself, and the second was 
because the NCI, who by that time had decided to do trials with it, generously 
gave us quite a large chunk of their own stock that they had set up for their own 
trials, which allowed us to go forward. And then, of course, Eve [Wiltshaw] set 
up the first randomized trial of carboplatin versus cisplatin in ovarian cancer, 
which she did on the back of what she calls her very tiny ovarian cancer practice, 
which I think was probably the biggest in the country, and we were able to do 
the trial, and show that carboplatin was just as good as cisplatin, but a lot less 
toxic. And to this day, carboplatin remains the most important single drug, and 
the preferred platinum analogue, for treating ovarian cancer. There have been 
countless other trials making the same comparison, and they all give the same 
answer virtually, except for one US trial that suggests that carboplatin may be a 
little bit better.72 
calman: Thanks, Hilary. Any further comments?
professor richard gralla: I’m from New York. Maybe I should take up the 
story from the 1973 Oxford meeting and what happened in the USA, unless Dr 
Harrap wants to go ahead. I was asked here mainly to talk about antiemetics, 
but I am going to reserve that for a little bit later. I was a witness to the early 
clinical studies after the Oxford meeting, and I started my medical oncology 
career at the same time as Hilary, in 1974, at the Memorial Sloan-Kettering 
Cancer Center. I read this nice blue book that the Proceedings of the Oxford 
71 See Sørensen et al. (1985).
72 Bookman et al. (2003).
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Conference were in, which was most fascinating in the first half of the book, 
because it talked about the chemistry, and most discouraging in the second 
half – a very fine, excellent anticancer drug, unfortunately too toxic to give to 
people. Certainly the NCI had that view. Steve Carter73 was one of the leaders of 
the meeting, and the real change, in my view, was the fact that there was another 
generation of physicians who were not invited to that meeting, who looked at it 
in another way. Now, as fortuitous as the use of cisplatin was in ovarian cancer 
– and again this is going back to the comment that was made earlier, that at any 
point this could have gone awry, and it was so wonderful that Don Higby had 
the testicular observations, Dr Harrap had the testicular observations, and that 
Dr Wiltshaw had the ovarian observations – but head and neck cancer was the 
exact opposite of this, there couldn’t have been a worse choice. Even though the 
drug is active there, because of the nature of head and neck cancer, the patients 
were all dehydrated before they got the cisplatin. So even at relatively lower 
doses, the drug was terrifically toxic, and excellent oncologists such as Alan 
Yagoda and Bob Wittes at that time said they didn’t want to touch it.74 
We have now reached 1974. I had the advantage of having so little knowledge, 
which had always been a plus in my career, that it was very helpful. And at 
that point a major figure in the development of these drugs, Steve [Esteban] 
Cvitkovic, who is now in Paris, came along, and Steve is a most irreverent 
individual; for those who know Steve, irreverent would be a soft word.75 Steve 
[Cvitkovic] was also interested in testicular cancer, and had as a research fellow 
done the first bleomycin infusions and could see that bleomycin was a drug of 
usefulness in this disease [testicular, head and neck cancer], but certainly with 
the older agents was of only very limited value.76 And that’s why Steve became 
particularly interested in cisplatin. Steve then asked, ‘How would you handle 
this kind of renal toxicity?’, which was the number one limiting factor in this 
area. He thought, ‘Well, when you read the literature you would either give a 
73 Dr Stephen (Steve) K Carter was Associate Director of Cancer Therapy Evaluation, Division of Cancer 
Treatment, National Cancer Institute, Bethesda, Maryland. 
74 Professor Richard Gralla wrote: ‘Alan Yagoda and Bob Wittes were at Memorial Sloan-Kettering Cancer 
Center in New York at that time’. E-mail to Dr Daphne Christie, 5 June 2007.
75 Dr Esteban [Steve] Cvitkovic has held appointments at Memorial Sloan-Kettering Cancer Center 
(New York), Columbia Presbyterian (New York), Instituto Mario Negri (Milan), Institut Gustave Roussy 
(Villejuif ), Hôpital Paul Brousse (Villejuif, France) and Hôpital St Louis (Paris) and was Senior Medical 
Consultant to AAI Oncology. 
76 See Carter and Blum (1974).
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chelating agent,’ – which made no sense medically as far as he was concerned – 
‘Or you would, as with mercury poisoning, give an osmotic diuresis’. So Steve 
then followed with hyperhydration and with an osmotic diuresis caused by 
simply giving mannitol. But Steve, being an extremely ethical physician, did 
not start with patients, he started with dogs. And, to do this, was exactly the 
observation that Sir Kenneth made, which was how you were able to just do that 
then. You could never do this today, and Steve always wanted answers quickly. 
So he went to the laboratory of Willet Whitmore, the famous urologist,77 and 
asked, ‘Can I borrow a dog or two?’ I think Dr Whitmore thought that he meant 
to walk it or something like that. Steve then went with the hyperhydration and 
the mannitol, which worked extremely well, and also tested some dogs with 
exactly the same dose of cis [cis-platinum] without the hydration mannitol, and 
it didn’t go well. This was published in 1977 in a series of three papers with 
both the histological deficits that were caused in the kidney by cisplatin with the 
preclinical safety and with the clinical effects in cancer.78
I remember one of the very first patients to receive high-dose cisplatin, which 
was then given with a very fancy hydrational aspect and later with mannitol, and 
it was to a young woman with a germ cell malignancy, with choriocarcinoma 
who had had everything, methotrexate, and 10 or 15 other drugs for brain 
metastases. I looked at my colleagues and asked, ‘Are you really going to treat 
her?’ Remarkably, she did very well, and at that point we knew that something 
special was going on. 
You have to look at the Memorial Sloan-Kettering at that time, a 600-bed hospital, 
all cancer patients. They had provided two closets for the administration of 
chemotherapy. It was an afterthought when they redesigned the building in the 
early 1970s, and there were no research nurses, etc., etc. Everything had to be 
done on its own. Cisplatin was treated as yet another Phase 1 drug, but one with 
a bad history, and another alkylating agent. Then these special things started to 
happen. Even Dr Robert Good, who was in charge of Memorial Sloan-Kettering 
at that time, felt that cancer would be cured by the immunologists, very quickly, 
and that Memorial Sloane-Kettering would be an immunobiology institution.79 
Therefore, as Steve and others were showing repeated cures in testicular cancer 
with Bob Golbey, they had to keep quiet about it, because this was as politically 
77 See Anon (1997).
78 See Hayes et al. (1977); Cvitkovic et al. (1977).
79 Dr Robert A Good (1922–2003) was Director of Sloan-Kettering Institute in 1973. See Hanson (2003).
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incorrect a development as one could have. So it was a remarkable occurrence 
at the time, but fortunately this improvement continued. 
I must mention another oncologist, Dr Lawrence (Larry) Einhorn, on the US 
side, who did wonderful work to complement the work that Drs Harrap and 
Wiltshaw were doing, which we knew very well.80 Larry took a different view: 
‘Let’s just divide the dose, give a small dose daily for five days and won’t this be 
safe?’ And by 1976, Larry Einhorn and Steve’s method of VAB-3 was presented 
at the American Society of Clinical Oncology (ASCO) in Toronto, Canada, 
which worked in all regimes for testicular cancer, complementing much of the 
work that was done here in the UK.81 
The last comment I will make on this is that the other contribution that Dr 
Rosenberg made over all this time was shepherding this drug, and he continued 
to have an extremely great interest in how the research was going from the 
preclinical to the clinical. He was at the meetings, he asked all the good 
questions, and he met everyone and was very interested in everyone’s research, 
and made sure that everybody stayed connected. This, I think, was a dramatic 
contribution to back up his initial remarkable observations.
calman: Thank you very much. I feel my past coming before me as I listen to all 
this because, like many people, I used to visit the Memorial Sloan-Kettering on 
a regular basis. I have two memories: one is I bought a set of cufflinks, and its 
logo is SKCC,82 which is also Sir Kenneth Charles Calman, and they are really 
nice to have. The second is that its full name, if you remember, is the Memorial 
Hospital for Cancer and Allied Diseases, and I remember seeing a patient there. 
I said, ‘Tell me what’s wrong with you’, and he said, ‘I’ve got an allied disease’. 
These are issues of communication which are pan-national.
harrap: I just wanted to link the chemistry to the clinical activity of cisplatin 
on the basis of a couple of remarks that Hilary [Calvert] made. He mentioned 
TNO-6,83 which is such a reactive compound; its solid-state structure just 
doesn’t exist in an aqueous solution. So reactivity is very important. One of the 
80 See Einhorn (2001).
81 VAB-3 protocol including vinblastine, actinomycin D and bleomycin. See, for example, Reynolds 
et al. (1981).
82 For a history and overview of the Memorial Sloan-Kettering Cancer Center (MSKCC) see www.mskcc.
org/mskcc/html/511.cfm (visited 2 May 2007).
83 See page 30.
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driving forces that led us towards carboplatin was the notion that in various 
structure–activity studies we had been doing, it was quite clear that kidney 
toxicity, which is the dose-limiting toxicity of cisplatin, appeared to relate to the 
chemical reactivity of the molecule. Now, of course, if you are trying to displace 
the nephrotoxicity of cisplatin in an analogue, you can monitor blood urea 
nitrogen in the structure–toxicity studies quite happily in rats and mice. But for 
the other toxicities, for example emesis, rodents don’t vomit, although rats do 
get stomach bloat. So we could look at stomach bloat and we could look at renal 
function in the rat. The other thing you can do, ultimately, if you are prepared 
to spend the money, is a ferret emesis test – and that’s a glorious opportunity for 
someone who wants to sit up all hours of the day and night, watching ferrets 
vomit.84 It’s very unpleasant, more so for the ferrets, I imagine. But anyway, 
we could do those three things, and that led us, as Hilary mentioned, to two 
compounds, carboplatin and JM-9, and again luck comes through and we went 
with carboplatin. But I didn’t want to give the impression that carboplatin just 
appeared, without there being any logic: there was a chemistry-linked logic, 
through to the pharmacology that led us to carboplatin, and then onwards to 
those platinum drugs which could be given orally and other platinum species 
that evaded the resistance mechanisms attributable to cisplatin resistance.85
calman: I think you are making a very good story out of it.
professor David grahame-smith:  I am a retired clinical pharmacologist 
and I want to ask Richard Gralla a question. The pharmacokinetics and 
pharmacodynamics of anticancer drugs have always been a great puzzle to 
me. Some years ago Adrian Harris and I investigated the pharmacokinetics, 
pharmacodynamics and therapeutic effects of cytosine arabinoside. That taught 
me how complicated these processes were. But you said you did a forced diuresis 
with mannitol and with lots of fluid to decrease the platinum-induced renal 
toxicity. What does that do to the half-life of the cisplatin, because you are 
presumably getting rid of it and diluting it? So what is all this doing to the 
plasma and intracellular concentrations of cisplatin and its anticancer action? 
I didn’t quite understand this, because it flashed by me. One says, ‘Oh my 
goodness that’s great, the patients aren’t getting nephrotoxicity, and they are still 
84 Ferrets are the animal model of choice for evaluating a compound’s antiemetic properties, because of the 
similarity to humans in neuroanatomy of the brain stem and stomach, and sensitivity to emesis-inducing 
agents. See Florczyk et al. (1981, 1982); Costall et al. (1987); Rudd et al. (1994). See also Wesley Miner’s 
contribution on pages 54–6 and Paul Andrew’s contribution on pages 44–6. 
85 Leyland-Jones et al. (1999); see also Ohmichi et al. (2005).
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getting better’. But can you explain the process to me, because it doesn’t make 
much sense?
gralla: I think the important fact is that I was truly a witness to this, and not 
the person who came up with what I think is a very good idea, so I don’t want 
to take credit for it. My understanding is that again you are driving a certain 
percentage of the cisplatin across the cells. You are basically giving it in excess. 
You need to be sure that you still have the chloride present, and once you get 
this across the cells, only a very small percentage of the cisplatin that you give is 
actually getting to where you need for it to become intracellular. So you need to 
get rid of the other 99 per cent, or 99+ per cent. However, this would be better 
answered by my clinical pharmacology colleagues.
calvert: I can give a slightly more technical answer. Cisplatin is fairly chemically 
reactive, and when you give a dose to somebody, you only ever get about 30 per 
cent of it back by urinary excretion, because the rest remains covalently bound 
to tissues. I think you can work out that someone, say, who has been treated for 
testicular cancer, and dies of something else 30 years later, will probably have more 
platinum in him, than the stuff they dig up in South Africa. So to a large part the 
excretion of cisplatin isn’t an issue because it doesn’t happen, it’s just partitioned out 
of the blood by covalent binding. But the 30 per cent or so that is excreted in the 
kidneys is excreted partly by glomerular filtration and partly by tubular secretion, 
because the clearance of platinum is 2.6 times higher than the glomerular filtration 
rate. I think the role of the hydration is that it increases the chloride content in the 
tubules and reduces the amount of reactive platinum there.86 
professor paul andrews: I wanted to pick up on something that Ken Harrap said 
about screening for the toxicity. You mentioned the gastric stasis model in the rodent. 
Can I check who came across that phenomenon as a potential as an index for emesis 
in non-vomiting species? Because the first paper I know is one – I think it is 1980 
– with Bradner and Schurig, and they made an interesting comment in the paper 
that that observation was an accidental discovery by one of the technicians who was 
doing post mortems on mice.87 That was the Bristol-Myers group in the USA, but I 
just wondered what your recollection is, because people are still publishing on that 
model today, including ourselves. Can you tell us about the origin of it? 
86 See, for example, Walker and Gale (1981). 
87 See Bradner and Schurig (1981), in particular page 99: ‘A second new test which is the result of a 
fortuitous observation by alert technicians is the so-called GI stasis model’. See also Florczyk et al. (1980).
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harrap: I think it was you [Paul Andrews] who suggested stomach bloat to us 
when we talked about it, so we are grateful to you for that. And yes, you are 
right; it is the Bristol-Myers group, John Schurig and colleagues, who suggested 
we think about the ferret emesis model.88 That’s quite right.
andrews: So, it is somewhere pre-1980 that people recognized the 
gastric bloat.
calman: We are going to talk quite a bit about the emesis area after tea, so we 
can perhaps pick up some of the areas around the early clinical development.
Thomson: I would like to make a couple of comments from the point of view of 
the chemistry. Cisplatin, as I explained, will lose its chloride ions rather readily, 
either in the absence of chloride or if it encounters another group that is a very 
effective nucleophile. Thiol is such a group. And, of course, the kidney damage 
presumably results from the platinum sticking to the thiol residues in the 
kidneys. I suppose we would call carboplatinum a pro-drug today. So, replacing 
the chloride ions with a chelating group, which will bind much more strongly 
to the platinum, yields something that is no longer a drug since it is quite 
unreactive to nucleophilic substitution. But, presumably, there’s a metabolic 
activation of the cis side of the molecule. 
I just want to pick up on one other point that has been aired, and that is the 
question of the comparison that was made early on between cisplatin and the 
classical alkylating agents. Although at first sight – and I drew the analogy myself 
– that seemed to be so, there were a lot of mechanistic studies in tissue culture, 
particularly by John Roberts at the Chester Beatty, to look at mechanism of action 
and ability of cells to repair DNA damage by cisplatin.89 It became clear that it 
was not a classical alkylating agent, and in fact we now understand some of the 
mechanism of action from the work of Steven Lippard and others, exactly how it 
binds to DNA and causes the DNA to kink [Figure 5].90 I remember in the early 
days, in the 1970s, there was a lot of discussion about the use of combination 
therapy. The notion being that if you had two drugs that had different mechanisms 
of action, then you would indeed have the effect of combination therapy. So I 
remember that being talked about as a driver for pushing platinum, because the 
mechanism of action was unlikely to be the same as a classical alkylating agent. 
88 See Florczyk et al. (1982). 
89 Thomson (1977); Roberts and Thomson (1979).
90 Steven Lippard from the Massachusetts Institute of Technology. See Cohen et al. (1979). 
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Perhaps I may make quite a different point, while I have the microphone. 
Rosenberg was very interested in the commercialization of everything he did. As 
a solid-state physicist before he came into this area, he discovered a phenomenon 
called persistent internal polarization in solid state physics, which was a process 
that underpinned the Xerox process; he just missed out being a multimillionaire 
by not holding a patent on the Xerox process. So patents for cisplatin were 
granted in 1979 and 1982.91 Barney always insisted that if such discoveries were 
not patented, then they would go no further, since the commercialization would 
not take place. There are some very interesting issues around that point, but not 
of consequence to this meeting.92
Williams: A very interesting feature for me, as a chemist, listening to the more 
clinical people here, is that I don’t know whether it has ever struck them, but 
cisplatinum is a very strange drug. In fact it doesn’t seem to have chemistry 
which is at all specific. There’s no built-in optical activity, there’s no built-in 
stereospecificity. So it will attack all proteins and nucleotides basically. And in 
fact crystallographers use platinum chemicals regularly for X-ray crystallography, 
because it’s a heavy atom which will bind to almost anything. I investigated 
91 Dr James Hoeschele wrote: ‘The anticancer activity of cisplatin and carboplatin were both discovered 
by Dr Barnett Rosenberg and his group at MSU. MSU held patents on both of these compounds. The 
inventions were exclusively licensed to Bristol-Myers, USA.’ E-mail to Dr Daphne Christie, 22 February 
2007. US Patent 4,177,263 December 4, 1979. Anti-animal tumour method. Rosenberg B, Van Camp L, 
Krigas T. US Patent 4,339,437 July 13, 1982. Antitumour method. Rosenberg B, Van Camp L, Krigas T. 
92 Professor Andrew Thomson wrote: ‘The original US patent, no. 4,177,263 on the use of cis-platin as 
an antitumour agent, was awarded in the names of Rosenberg, Van Camp and Krigas and assigned to 
the Research Corporation (RC). [The RC, a US charitable foundation established in 1912 to promote 
“the advancement and extension of technical and scientific investigation, research, experimentation and 
education” by making grants, known today as Research Corporation Technology (RCT), 405 Lexington 
Avenue, New York.] In 1981 A J Thomson asked B Rosenberg to explain the reasons for his exclusion from 
the patent given the published statement by Rosenberg that he, A J T, was the “the true discoverer” of cis-
platin (see note 23). Legal advice concluded that the inventorship “is correctly stated” in patent 4,177,263 
and that the exclusion of A J Thomson from the patent was a “technical matter of US Patent Law” not 
further specified [letter from Robert J Saunders, Jr, counsel for the RC dated 8 January 1982]. In 2000 
four generic drug companies found themselves defending a charge of infringing a cis-platin patent (no. 
5,562,925) against the RC and Bristol-Myers (exclusive licensee of cis-platin). This latter patent, issued in 
1996, was identical to the original patent, 4,177,263, other than “protect from light” had been added. This 
patent was declared invalid in a judgment in July 2000 by the US District Court of New Jersey on several 
grounds, but notably that the necessity to protect cis-platin from light was already published in 1967 in 
the Journal of Biological Chemistry 242: 1347, by Rosenberg, Grimley, Van Camp and Thomson. Hence, 
four generic companies began the formulation of cis-platin, substantially lowering the cost of a course of 
treatment.’ Note to Dr Daphne Christie, 18 February 2007.
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that a little with Sir David Phillips’ group and it just binds to most proteins.93 
So when you think about the toxicity, I think cisplatinum toxicity is to some 
degree everywhere, and it happens to be lucky that in some way it gets through 
a little bit better to the cancer cell than to other cells. Exactly how that happens 
would be very interesting to know, because if we knew that, we might learn a 
great deal about how drugs can actually work, which is nothing to do with old-
fashioned ideas of specificity.
professor kenneth Bagshawe: There has been a certain amount of reminiscing about 
the early days of clinical oncology, and I would like to add to that. Fifty years ago I 
was a senior registrar at St Mary’s Hospital, London, along by Paddington Railway 
station. I was a senior registrar in medicine, with a vague idea about becoming a 
cardiologist. One day there was a patient who came in; she was 17 years of age, 
and she was the most breathless person I have ever seen in my life. She had crawled 
into the hospital. The casualty admission card read, ‘hysterical hyperventilation, 
good teaching case’. I looked at her and, as a budding cardiologist, I found she 
had a biggish right heart and the chest X-ray was clear. She denied having been 
pregnant, but she had pulmonary hypertension, hypertension in the pulmonary 
circuit. She died three days later, and the autopsy was done on a Saturday morning 
by the Professor of Pathology, M Price, and he said, ‘Oh, look, she’s been a naughty 
girl, she’s had pelvic sepsis and it’s spread to her lungs’. But my predecessor was at 
the autopsy, a senior registrar, Dr Adrian Joekes, who had been a senior registrar 
for about 20 years, and he said, ‘That’s not pelvic sepsis, that’s choriocarcinoma. 
There was a case like this at the Hammersmith ten years ago’. And it proved to be 
choriocarcinoma, occluding her pulmonary blood vessels. 
Six months later, I was called to the gynaecology ward to see a woman who had 
had a hysterectomy for bleeding, but the uterus didn’t contain any tumour and 
she went home on anticoagulants and a diagnosis of pulmonary embolism – a 
very common event after hysterectomy. She came back to the hospital a few weeks 
later, short of breath, and by chance it was our admission day, and we put her 
back on anticoagulants, but she continued to deteriorate. I thought it couldn’t 
be another case of choriocarcinoma, but still went to see the pathologists, and 
they said, ‘Ken, you have got it on your brain, you’re crazy, it couldn’t be another 
case of choriocarcinoma, they are very rare anyway, and that Hammersmith case 
is unique, it is the only one in the literature’. So she continued to deteriorate 
and after about four or five weeks she was in an oxygen tent, because you weren’t 
allowed to die in the 1950s without being put in an oxygen tent, it hastened 
93 Petsko et al. (1978).
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one’s departure, but that wasn’t known until a few years later.94 There was one 
other way of making sure it could be a choriocarcinoma, and that was to have 
a pregnancy test, but there were no pregnancy tests available at that time, other 
than very crude biological tests, one called the Friedman test.95 So I took her 
urine to the lab. The man who ran the lab had lost an eye, and when he was 
confronted by a junior doctor asking for something that he thought was stupid, 
he removed his glass eye, polished it on a red and white spotted handkerchief 
that he kept in his top pocket. If you were still there when he put his eye 
back in its socket, which wasn’t usual, because you usually disappeared on these 
occasions, anticipating his conclusion, he said he wasn’t going to sacrifice a 
rabbit for a woman who couldn’t be pregnant and the pathologists said there 
was no tumour in the uterus. Anyway she was obviously dying, and that was 
on a Wednesday. As I came back from the lab I met the medical superintendent 
and he said, ‘Well, old so and so is always very interested in hospital scandal, so 
why didn’t I send the urine under a pseudonym?’ So we went through all the 
bits of hospital scandal we knew at the time, and one of the chief surgeons was 
alleged to be having an affair with one of the nurses. 
So I found this lass, and asked if she would mind sending in this urine under 
her name. She thought that was a great joke. So off it went on the Wednesday. 
On the Friday afternoon the consultant came round and said, ‘You had better 
phone the husband, she is not going to last the weekend’. That evening after the 
ward round, the nurse appeared with this form saying, ‘I must be very pregnant, 
it says Friedman test strongly positive’. So this was another choriocarcinoma. 
The pharmacy was closed. I got 6-mercaptopurine from the pharmacy, and we 
gave her big doses of 6-MP over the weekend, and on the Monday morning 
when I went in she was out of the oxygen tent, sitting up eating breakfast. She is 
still alive 49 years later.96 And then we had another case of a girl presenting with 
a retinal metastasis from choriocarcinoma, and she is also still alive 48 years 
later. So this led me to look at gestational choriocarcinoma. 
And then, of course, because there are testicular tumours that also have 
choriocarcinoma-like elements, I began to get these referred. And jumping 
ahead a few years, we were getting about 65–70 per cent of the gestational 
94 See, for example, Davis (1952).
95 A pregnancy test in which a female rabbit is given an intravenous injection of urine from the patient; 
formation of corpora lutea in the ovaries indicates a positive test. See McNeile and Reynolds (1933).
96 Bagshawe and Brooks (1959).
The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer
40
tumours through into remission.97 We were getting nowhere with the germ cell 
tumours. Between 1962 and 1968 I treated 28 patients, who presented with 
massive disease, and they responded to methotrexate, they also responded to 
other drugs that we threw at them, but none of them went into remission. 
And then in 1968 we got two patients through sustained remission and from 
then on the remission rate started to improve. We were juggling with quite a 
number of drugs at the time. I was involved in the early discussions around 
cisplatin and when it became available we got some. It was very disappointing 
in the gestational tumours, it didn’t really add very much, and that was a big 
disappointment, but we did use it in the germ cell tumours, the testicular 
cancers, teratomas and ovarian germ cell cancers, and we began to get much 
improved results. But, of course, it was overtaken as a drug, both in gestational 
trophoblastic tumours and in the germ cell tumours, by etoposide, which came 
along. I think we were the first to use etoposide in those tumours, in 1977.98 
calman: These stories, and some of you will know I have a particular interest 
in storytelling, become very real, and again those of us who were around at 
that time remember that background very vividly. Any other comments about 
clinical things?
calvert: Just going back to stories. In the early 1980s when we were doing the 
Phase 1 of carboplatin, there was a patient who came from overseas, where they 
didn’t have a good health care system, but who couldn’t afford to pay any more 
for the private treatment he had been receiving, and so he volunteered to go on 
to the Phase 1. He had a seminoma, very advanced seminoma, with metastases 
all over the place, which shrivelled up and disappeared promptly after his first 
dose of carboplatin. And that was the first indication that a single dose of 
carboplatin might be adequate treatment for seminoma. Subsequently, after I 
moved to Newcastle, people were normally getting four doses, because nobody 
dared to give them less really, nobody was clear whether you actually needed to 
give four. And we had a patient from Franklyn Jail, who had done something 
particularly nasty in the past, so he used to come along chained to warders to 
get his chemotherapy. And he got his first dose and when he came back for his 
second dose, I was a bit annoyed that morning, because I hadn’t been able to 
get into my parking space, because there was a white van in it, and as he arrived 
at the hospital, a load of chaps jumped out of the white van and fired guns in 
97 See Bagshawe (1969). 
98 Newlands and Bagshawe (1977).
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the air, and extracted him, and took him away, so that in fact he never received 
his second dose of chemotherapy. So we were very interested in this, because 
we thought they would find him eventually, and we could follow him up to see 
whether he actually needed a second dose or not. [From the floor: This is not 
randomized.] But in fact that experiment didn’t work because the people who 
sprang him didn’t have a charitable intention and he’s buried under a motorway 
somewhere now, I think. But the end of the story is that there have been formal 
studies done now, and although I don’t treat them myself, I think it’s fairly 
common practice to give just the single dose.
calman: Franklyn Jail, for those of you who don’t know, is in my home town of 
Durham. So that is of interest to me, too. Now other comments, we have got 
about 10 minutes before we break for tea.
hoeschele: This comment dips back in time. It’s an historical comment. Even 
as cisplatin was showing good antitumour results in vitro and in clinical trials, 
there was still feeling on the part of Dr Rosenberg, primarily in the earlier 
phase of the preclinical studies, that there might still be a ‘magical ingredient’ 
in the prepared solutions (of cisplatin but not related to cisplatin) that could 
account for the activity being observed. Perhaps this was related to the feeling, 
as a result of the disappointing response and toxic response of arsenic and 
mercury compounds, that the idea of a metal compound being a useful entity 
still occupied a little bit of a question mark in his mind: not a strong feeling, but 
he mentioned it several times in the course of working with him.
Dr penelope Brock: I have been asked to come here by Dr Jon Pritchard, 
who is my mentor and teacher.99 I thought I would introduce, perhaps, the 
paediatric side, the clinical paediatric side. It was Eve Wiltshaw, I understand 
from Jon, who first mentioned cisplatin to him. He went to a meeting in 
Chicago, apparently at the end of the 1970s, and he heard [Larry] Einhorn 
speak and he came back very excited about using this new drug. But he had 
also read an abstract from a colleague from Turkey. We have quite a close-knit 
international paediatric oncology group, and he went over to Turkey and he 
looked at the notes – although he couldn’t read the Turkish somebody helped 
him through the notes – to see that patients had been treated with cisplatin and 
were responding. So he came back to London – he was consultant oncologist 
and senior lecturer at Great Ormond Street [London] – and he decided to look 
99 Dr Jon Pritchard (1942–2007) introduced cisplatin for the treatment of childhood liver tumours. He died 
shortly after this meeting, on 20 January 2007. See Brown (2007) and page 102.
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into this drug. Julie here [Mrs Julie Wenn] is one of the first patients that Jon 
treated with cisplatin in 1981. I was able to find her notes [before this meeting] 
and she was treated in May 1981, I think. It was really very forward-looking 
of Jon Pritchard to start using cisplatin in children, because we were very, very 
nervous of this drug. I remember as a house officer being told about the drug 
and how dangerous it was and we were very nervous about giving it to children, 
particularly to infants, worried about whether their renal function would go 
on developing, because the glomerular filtration rate (GFR) in children only 
reaches a normal value at about the age of two years. Jon later on asked me to do 
my doctorate on cisplatin toxicity in infants and children. We were able to give 
it to a number of infants and then publish data on the toxicity of it.100
One other point that I would like to make which I haven’t heard anything on 
yet, and I think this was very interesting, is that when I started looking at the 
toxicity, much of the early work was unable to tell us a lot of detail about the 
hearing loss, and when we started using it in children, what really struck us 
enormously was that their hearing went off.101 When we started using it at high 
doses, at 200 mg/m2, per cycle,102 the hearing would go off per cycle. It was Sue 
Bellman, who was the consultant audiologist at Great Ormond Street, who came 
up to me, a young enthusiastic registrar, and said, ‘Penelope, we have got to look 
into this, these children are losing their hearing and they are losing it per cycle, 
what are you doing?’ We had started using a higher dose of cisplatin, and it was 
then that I got interested in making a grading system which is now being used 
worldwide, known as Brock grading and used to grade toxicity in international 
clinical trials.103 Because our tumours are so rare, we have to collaborate, and 
Jon Pritchard formed a liver tumour group using cisplatin and doxorubicin in 
a pilot study in the early 1980s. Liver tumours, particularly hepatoblastoma, 
which only occurs in children, is now studied in 36 different countries in a 
clinical trial group called the SIOPEL group.104 We have been able to move on 
100 Brock et al. (1992).
101 Brock and Bellman (1991).
102 Dr Penelope Brock wrote: ‘Chemotherapy, as many other medications in children, is dosed in mg/m
2 
or 
mg/kg body weight.’ E-mail to Dr Daphne Christie, 6 June 2007.
103 Brock et al. (1988, 1991).
104 The International Childhood Liver Tumour Strategy Group (SIOPEL) is a group of medical specialists 
founded in 1988 under the umbrella of the International Society of Paediatric Oncology (SIOP), to 
promote basic and clinical research on childhood malignant neoplasm of the liver, mainly hepatoblastoma 
and hepatocellular carcinoma. See www.siopel.org/ (visited 12 February 2007).
The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer
43
to discover that cisplatin is the most active agent in hepatoblastoma and we now 
use cisplatin monotherapy in hepatoblastoma. I think it is an example where 
there are very few tumours where one drug is actually not only the best drug, 
but is adequate to cause more than an 80 per cent cure with surgery in standard 
risk malignant disease. So, that is part of the paediatric story.
gralla: I would like to make a couple of comments on the ototoxicity which 
is indeed a neurotoxicity as well. And with the hydration and mannitol, 
again which was done in the early 1970s, no longer was nephrotoxicity the 
limiting toxicity, it was neurotoxicity, and the reason that we did not give 200 
mg/m2, which, of course, was given for a while in ovarian cancer and some other 
cancers, was the neurotoxicity. The ototoxicity was well described in adults by 
the mid-1970s, and the summary paper by Dan Von Hoff, published in Cancer 
Treatment Reports, looks at that rather carefully as well.105 But basically, it’s not 
that one could not give more than 120 mg/m2, it’s just one should not give more 
than 120 mg/m2, and unfortunately this was rediscovered in the 1980s. 
I would like to make a comment also on another clinical aspect, how interesting 
carboplatin is and how interesting the research in ovarian cancer has been with 
carboplatin. As Hilary has mentioned, there are multiple studies that support 
the equality of the two platins in ovarian cancer. However, that does not occur 
in many other cancers, and cisplatin is the superior drug in testicular cancer 
as shown in randomized trials. This is not our topic for today exactly, but in 
testicular cancer it is most unusual for people to use carboplatin, and there will 
soon be published a third meta-analysis in lung cancer,106 where platinums are 
not very active, but they are a little active, and there is a modest improvement 
with cis over carbo. This is an area where Hilary and I have enjoyed arm wrestling 
for quite some time, but the interesting thing to me, relating to our seminar, 
is that going back to the late-1960s and early-1970s, cisplatin was identified as 
the important drug to carry forth in clinical trials, and it has been very difficult 
to replace this agent. Unfortunately, it’s many, many years now. There is the 
addition of carboplatin and in appropriate patients oxaliplatin, which seems to 
expand the horizon of the platinum drugs, but it is interesting that it has been 
difficult to exceed cisplatin over this time. Getting back to Professor Williams’s 
comments and the early observations, why in the world did this drug work, and 
 
105 Von Hoff et al. (1979).
106 Jiang et al. (2006). 
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how and why can we not identify its selectivity or the lack of selectivity, I think 
is very interesting. There is still a lot to learn.
calman: I am going to call a break for tea now. We have had two eponyms this 
afternoon, with the Brock grading and the Calvert formula. Perhaps your task 
over tea is to see if there are any other eponyms that we could add. 
We have covered chemistry and some of the early clinical work; now we have to 
move on to another big area that developed and that’s related to the antiemetic 
area, and I want to ask Paul Andrews, perhaps, to say a few words at the 
beginning to stimulate discussion.
andrews: I think this next section on antiemesis and some of the side-effects of 
chemotherapy is really an interesting story of, I suppose, two or three parts. One 
part is the development of the appropriate animal model to study emesis, and as 
we have heard, rodents – rats and mice – don’t vomit, so clearly you can’t study 
the emetic effects of cisplatin directly and thereby look at the antiemetic effects. 
So there is a key component here: the development of the animal model. 
I was involved during my PhD thesis, fortuitously again, noticing that ferrets 
vomited very readily, even under anaesthesia. Then when I moved from Sheffield to 
Edinburgh and was looking for funding, I applied to the Smith Kline Foundation 
and received a £1200 grant to look at the role of the vagus in cisplatin-induced 
emesis and that was, I think, in 1981. So that was again looking at an appropriate 
model, and, of course, this has been taken on. Perhaps, we could talk to John Rudd 
later, who was one of the people who developed a model for delayed cisplatin 
emesis, and was one of the people who sat there for three days, looking at what 
happened to mimic the clinical situation; he might comment later. 
So the model is critical, and this ferret model was very important, because it 
was used for the development of the 5HT3 receptor antagonists, but also set the 
scene for the development of the NK1 antagonists, which also are antiemetic, 
and which came into clinical use just a couple of years ago.107 So the model 
clearly has two drug successes at predicting for antiemetic use in this area. 
The second part of the story relates to the discovery of the 5HT3 antagonists 
themselves, a whole new class of agent, which have very potent antiemetic 
effects.108 It is a very interesting study of drug development which essentially, 
107 Sanger (2004); Andrews and Rudd (2004): 359–440.
108 See, for example, Oxford et al. (1992); Kilpatrick et al. (1990).
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at the time, involved on the emetic side, workers at Beecham in those days, 
and we will hear Gareth Sanger and Wes Miner, who were on one of the first 
two publications demonstrating the antiemetic effect of a 5HT3 antagonist in 
the ferret.109 
The other major group working at the time on emesis was at Glaxo, and 
representing them here today are Robert Naylor and David Tattersall, who 
were at Bradford University – Robert Naylor is still there – and involved very 
closely with the Glaxo programme, so they can comment on that aspect of 
development. It is a very interesting one, because I think, as they will both allude 
to the other component of this, which was a clinical observation. That clinical 
observation was made by Richard Gralla and used what we pharmacologists and 
physiologists would call ‘industrial’ doses of metoclopramide and found that 
it worked rather better than lower doses of metoclopramide as an antiemetic 
in chemotherapy patients.110 And of course that, for anybody who was alert, 
that might set them wondering, ‘Well, can the pharmacology that we knew 
from metoclopramide explain this effect of a very, very high dose?’ And that 
109 Miner and Sanger (1986).
110 Gralla et al. (1981). See also Gralla (1983).
Figure 8: (left to right): Gareth Sanger, Wesley Miner, Robert Naylor, David Tattersall at the Witness 
Seminar, 4 April 2006. Photograph taken by Mrs Lois Reynolds, and provided by Dr Gareth Sanger.
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was one of the important clues in the discovery and development of the 5HT3 
antagonist. So there is quite a lot of serendipity again involved in even this part 
of the story. Perhaps I can hand back to the Chair. We have a number of the 
people here from the very first discoveries of the antiemetic effects.
gralla: Cisplatin had an unintended but major contribution to make to medical 
oncology. The reason is that cisplatin led to great benefits because of this emesis 
and all the interest that there was in emesis and the study of the control of emesis 
now cuts across to almost every other anticancer drug where the control is as 
good or better. Cisplatin ultimately caused a revolution in cancer care, in that 
having the ability to control emesis meant that patients generally could be treated 
on an outpatient or ambulatory basis, rather than having to stay in the hospital 
because of the dehydration and electrolyte imbalance that often occurred. This 
benefit of looking at the emesis was definitely stirred by cisplatin. 
My involvement with my first protocol with cisplatin was about 30 years ago – 
for a treatment-related protocol that is, not Phase 1 or 2 – and was with lung 
cancer. There we saw benefits against lung cancer with cisplatin.111 Indeed the 
magnitude is nothing like that seen with ovarian or testicular cancer, but it was 
the first time that we had seen a duration of response that would imply the 
likelihood of survival benefit. This was something different, something that 
definitely bothered a lot of people for 10 or 15 years in lung cancer oncology; 
they didn’t want to believe that you could actually improve survival in this 
disease. With the second protocol, we had an agent to marry with cisplatin, 
a vinca alkaloid at that point, and we started to see very excellent responses 
with this combination. The vinca alkaloids eventually led to vinblastine which 
is still one of the standard agents used with cisplatin, or carboplatin, in the 
treatment of lung cancer.112 So when the problem of the renal toxicity had been 
answered, cisplatin’s use became mandatory, but if we were going to continue to 
use cisplatin as a drug to produce modest benefits in survival and in palliation 
for other areas, we had to find a good antiemetic, and find a useful approach 
to dealing with emesis. It wasn’t because there were editorials in journals at this 
point saying, ‘Oh, we must find a good antiemetic’. It was because of people like 
my patients, a physician’s patient, people like Julie who is with us here today, 
who were experiencing all this emesis at that time, while getting benefits from 
111 Gralla et al. (1979).
112 See, for example, Kris et al. (1985).
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the cisplatin, but with these terribly discouraging, dispiriting and distressing 
side-effects of emesis.
Cisplatin was a perfect model and I have always held that the human predicts 
the animal fairly well. Sometimes the other way works too. But with the human, 
100 per cent of patients getting cisplatin will have emesis. There is supposedly 
one report, and I would like to see the original case report, of somebody who just 
had horrible nausea and didn’t vomit for about 24-and-a-half hours, but other 
than that, if you have a drug that prevents emesis with cisplatin, it’s the drug 
that’s doing it. So therefore you have a very good human model as far as emesis 
is concerned. Our approach in the late 1970s when we looked at the problem 
was to look first at the world literature of clinical trials with antiemetics. I did 
this, and because I am a slow reader it took me the entire Sunday afternoon to 
review the literature, and I was taking notes as I went along. 
The other thing that we felt that we had to develop was a decent methodology. 
Our key to the methodology, for which we are given a fair amount of credit, was 
‘if you are going to measure an antiemetic, find out if it prevents emesis’. This 
seems like a very profound observation, but this was about it. What had happened 
before was that people measured things like satisfaction, psychological concepts, 
etc., and we said that an antiemetic should prevent nausea and vomiting; if it 
doesn’t do that, what kind of antiemetic is it? It was that straightforward, maybe 
a little bit more. When we looked at the drugs that were available at the time, 
we knew that several of them were not good – phenothiazines, which block 
dopamine D2 receptors, and the cannabinoids, which are widely publicized in 
the lay press.113 These drugs do work, but not very well, which is unfortunate. 
And so we felt that we had to move on. Another advantage that we had in our 
group was a lack of experience with metoclopramide as an antiemetic. In the 
1970s it was an investigational drug in the USA, even though it had been widely 
available in most countries in the world, and we felt that the dose was not well 
established for the indication of emesis. Clearly the pharmacodynamics of what 
happened in the gut were well known, but not the dose to prevent emesis. 
And so we thought about it from the viewpoint of Phase 1–2 doctors: ‘Let’s 
escalate the dose, let’s see what happens. Is it safe?’ I then looked at the world’s 
suicide literature, and it looked as though it was impossible to kill yourself with 
the drug, so that sounded good. I called my colleagues in Europe and South 
113 See, for example, Lucas (1983); Morris (1997); Voth and Schwartz (1997). See also Sanger (1993): 
179–210.
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America, who had a lot of experience with the drug, and they said, ‘No, no, no, 
you cannot escalate the dose of this drug’, and I said, ‘Have you ever done it? 
Have you ever given more than 10 or 20 mg?’ ‘No’, they said. So then I knew 
we were on to something. The lack of experience made me think that we could 
do this. 
Sir Kenneth has talked about the way that protocols were written in those 
days. Our protocol looking at metoclopramide as an antiemetic was perhaps 
three pages long, the consent form was a good half page, and we only had 
three dose escalation steps in the protocol and then we had a fourth line which 
said further escalations may be done, but would not exceed 33 per cent. Once 
you get up to 1 mg/kg, 33 per cent is a pretty nice escalation. We got to 3 
mg/kg per dose, at which point the sponsor came by and said, ‘Stop. OK, 
what have you done here? We cannot give doses like this; we are going to 
take away the drug’. I asked, ‘Don’t you want to see the results?’ To our great 
surprise, at 2–3 mg/kg we were getting complete control of emesis in about 40 
per cent of patients. Just about the same as with 5HT3 antagonists. This was 
just something amazing to us, we were just scratching our heads, we couldn’t 
understand it; we had gone up stepwise: we looked at infusions, and we looked 
at intermittent aspects. But there were problems: one, it was inconvenient. Our 
first protocol had five doses of metoclopramide at the high doses, which meant 
that it was very difficult to give it on an outpatient basis. We later refined that 
to two doses. It did have dystonic reactions, and these really weren’t so bad in 
most adults, but for younger people below age 30, and for children, this was 
difficult. We did a study in children and we said you could use it for one day 
but not beyond.114 We also then started to notice delayed emesis. This was a 
real shocker, because we had never seen anybody who hadn’t had emesis on 
the day of chemotherapy, and then we had some patients who had complete 
control in the first 24 hours, and thereafter started to have emesis. This just 
came out of nowhere and so we just did not understand what was going on, 
but knew that we had to do more. And, of course, 60 per cent of patients still 
had emesis. 
Another parallel observation at that time, and I am sorry that Matti Aapro from 
Geneva can’t be here, because Matti did a lot of work with corticosteroids, and we 
still don’t know how they worked in emesis, but simply by adding a single dose 
114 See, for example, Allen et al. (1985).
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of dexamethasone, the control went up from 40 to 60 per cent.115 So suddenly 
we were approaching having two-thirds of the patients with no acute emesis, 
and some advantages in delayed emesis, especially with the corticosteroids, but 
a little bit with metoclopramide. We asked ourselves the same question that 
Wes Miner and I were talking about: why the high dose? Why do you need the 
high dose of metoclopramide? We thought it was probably working by blocking 
another receptor, but which one, and we really didn’t know which one. This 
led, then, to putting these observations together, to further work that led to the 
discovery and synthesis of the serotonin [5-hydroxytryptamine, 5HT] receptor 
antagonists, which so many people in this room contributed to and will tell that 
story. Then later on for the NK1 receptor antagonists, to the point that we now 
have 80–90 per cent of patients completely protected against acute emesis with 
cisplatin and 60–70 per cent with the delayed emesis. It’s been quite a surprise to 
many of us. Again, the contributions are to the control of emesis with cisplatin, 
but later to other chemotherapeutic drugs as well, and to the way in which we 
administer antiemetics, and the way we administer chemotherapy.
calman: Thank you very much. Who wants to continue the story? I am looking 
at my colleagues, particularly in the drug industry.
Dr gareth sanger: You can tell I am from industry. I am the only non-
clinician not wearing a suit here. I would like to draw together perhaps four 
different strands of research, one beautifully told by Richard Gralla. Back in 
the early 1980s he published his paper to show that a relatively high dose of 
metoclopramide could take out cisplatin-induced vomiting.116 Certainly not an 
industrial dose because there is no way you would get away with that, more an 
heroic clinical dose. 
But at that time there were other strands of research. I will take you back to some 
work done by Dr John Fozard who, when I was a PhD student in Manchester, 
was working upstairs in the pharmacology department, characterizing what was 
then known as the 5HT M receptor; M for morphine – that was the classification 
that predated 5HT3 – as defined by Gaddum.
117 
115 Aapro and Alberts (1981); Kris et al. (1989).
116 Gralla et al. (1981).
117 Gaddum and Picarelli (1957) suggested that 5HT-induced contractions of the guinea-pig isolated 
ileum were mediated by a morphine-sensitive ‘M’ receptor located on the parasympathetic ganglion and a 
dibenzyline-sensitive ‘D’ receptor located on the smooth muscle. See also Bradley et al. (1986).
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Figure 9: Sir John Gaddum, Department of Pharmacology,  
University of Edinburgh, 1957. Wellcome Library, London.
118
Fozard was interested in the 5HT M receptor119 and was developing quite 
beautiful models of characterizing this receptor, with everybody wondering 
where his next research grant was going to come from, because there wasn’t 
much interest in that area of research. He eventually left the University 
of Manchester, and moved to Merrell Dow in France and persuaded that 
organization to identify selective 5HT3 receptor antagonists. They were the first 
published compounds. There was one whose number I can’t remember, but 
one in particular, MDL 72222, was published and eventually went into clinical 
trials for the treatment of migraine, where there was some encouragement, but 
it was never developed and you could say that line of research failed.120 However, 
John [Fozard] identified certain animal models: the isolated rabbit heart, which 
could be used to characterize the pharmacology of the 5HT3 receptor; the 
von Bezold–Jarisch rat reflex, which is a reflex evoked in anaesthetized or 
118 Archives and Manuscripts, Wellcome Library, London, L0025591.
119 Fozard (1984a); Bradley et al. (1986). See also the International Union of Pharmacology classification of 
receptors for 5-hydroxytryptamine (serotonin), Hoyer et al. (1994).
120 Loisy et al. (1985).
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conscious rats, following intravenous injection of 5HT.121 Effectively, in this 
model, he was activating the 5HT3 receptors on the vagal afferents projecting 
from the heart to the brain stem and then projecting back down again, to cause 
a whole sequelae of reflex functions. But von Bezold–Jarisch, in particular, 
focused on the rapid bradycardia that was evoked by that reflex. You could use 
that as a tool for examining the pharmacodynamic characteristics of any new 
5HT3 receptor antagonist; John was doing that kind of work. 
The other line of research, and perhaps the third after Richard’s [Gralla] and 
John’s [Fozard] work, was that carried out by ourselves and by our competitors, 
who are now also my friends, because of various industrial mergers. In particular, 
work going on in two different companies, one directed by Brian Richardson 
at the then Sandoz (now a part of Novartis) company in Switzerland.122 They 
were identifying a new 5HT3 receptor antagonist, known as tropisetron. He 
identified that compound, took it to clinical trials, primarily for the treatment 
of pain, developing a nice pharmacodynamic model in man, called the ‘blister-
base pain’, where you form a little blister on the hand and you can then take out 
the pain sensation with 5HT3 receptor antagonists.
123 A lot of us then speculated 
about the role of 5HT3 in bee stings, nettle stings and all sorts of things developed 
from that. Sandoz took that compound for the treatment of migraine. Again, 
it didn’t work. However, tropisetron is now launched and registered for the 
treatment of nausea and vomiting. Another company involved was the then 
Glaxo company, now GlaxoSmithKline, in which I currently work.124 They took 
a different approach. They took the different 5HT receptors and said, ‘Let’s sort 
this out, let’s identify novel receptor agonists and antagonists for the different 
receptors’. And even though they were competitors to Sandoz at the time, I 
have to admit that was a tremendously brave approach, because it meant that 
they identified the ligand and then went fishing for the disease. That’s difficult-
to-sustain financial backing, even within a company. But they did that, and 
they identified a compound known as ondansetron. That team, led by Mike 
Tyers, eventually went into various CNS animal-based behavioural models, and 
Bob Naylor will tell you a lot more about that, because they worked closely 
121 Aviado and Guevara Aviado (2001). 
122 Novartis was created in 1996 from the merger of the Swiss-based companies, Ciba-Geigy and Sandoz. 
For a history see www.novartis.com/about_novartis/en/history.shtml (visited 30 November 2006).
123 Richardson et al. (1985). See Appendix 2 for structural formulae of some 5HT3 receptor antagonists.
124 Glaxo Wellcome plc and SmithKline Beecham plc merged in 2001 to become GlaxoSmithKline plc 
(GSK). For a history see www.gsk.com/about/history.htm (visited 30 November 2006).
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together. They then took the compound into migraine, following John Fozard’s 
and Brian Richardson’s idea, and showed that it didn’t work very well, but it 
did take out the nausea or vomiting.125 From there they took that into cancer 
chemotherapy. I haven’t been able to speak to Mike Tyers or any of the people 
who were involved in that work, but Mike and I were lucky enough to receive the 
1998 Discoverers Award from the Pharmaceutical Research and Manufacturers 
of America Association (PhRMA), in which the history of these two different 
discoveries are laid out. There’s quite a lot of documentary stuff in the books 
that I have brought with me.126 
The final line of research was conducted in the then Beecham Research 
Laboratories (now part of GlaxoSmithKline).127 We were, effectively, trying 
to take metoclopramide apart to develop novel gastric prokinetics and novel 
antiemetics that didn’t have the CNS side-effects, such as the extrapyramidal 
reactions evoked by metoclopramide and certain other dopamine D2 receptor 
antagonists.128 It was done using a kind of classical biological research, which 
you would almost regard as unethical today. It was, ‘Let’s take a molecule, 
and let’s screen it in conscious animals’. You would never ever do that now. 
Nevertheless, using that kind of process, they were able to identify certain 
molecules that appeared to have a selective action. I got hired somewhere in the 
middle of that, put down at a desk in a spare room and told to find something 
to do, literally. I eventually developed my own job description, which was to 
figure out how metoclopramide worked. To cut a very long story short, out 
of that work came the identification of what we call the myenteric 5HT-like 
receptor, now known as the 5HT4 receptor.
129 So, we set the foundations for 
that discovery and we linked the 5HT4 receptor to the gastric prokinetic activity 
of metoclopramide. In making this link, we also said that metoclopramide did 
not act as a gastric prokinetic because it antagonized at the D2 receptor. At the 
time, this was a novel argument. As part of this investigation, we looked at the 
entire pharmacology of metoclopramide and identified a rank order of activity 
of metoclopramide at a range of different receptors, recognizing that very low 
doses or low concentrations of the drug activated what became known as the 
125 See, for example, Stables et al. (1987).
126 PhRMA (Pharmaceutical Research and Manufacturers of America) (1998). See also page 103.
127 For a history see http://search.gsk.com/cgi-bin/RS.cgi (visited 30 November 2006).
128 Kris et al. (1983).
129 Dumuis et al. (1989).
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5HT4 receptor, and also antagonized at the D2 receptor.
130 If you bumped the 
concentrations up, you can show that it then antagonizes at the 5HT3 receptor 
(and we drew heavily from John Fozard’s work there [Manchester, and then 
at Merrell Dow]) and also antagonized the alpha-2 adrenoceptor and, at even 
higher concentrations, inhibited cholinesterase activity. So it was a really dirty 
compound. But we took that kind of biology, analysed it, and we then took 
selected molecules that we were generating to test out ideas. We had identified 
what was a pure gastric prokinetic compound that stimulated gastric motility in 
rats and that did not block apomorphine-induced vomiting. In other words, it 
didn’t appear to be a dopamine receptor antagonist, so, based on the knowledge 
at the time, it should not have been an antiemetic.131 
By then, we knew that this molecule also antagonized at the 5HT M receptor 
(5HT3). Simultaneously, Wes Miner at Beecham Pharmaceuticals was developing 
the conscious ferret model to test new D2 receptor antagonists and antiemetic 
compounds. I gave this molecule to Wes for testing. As you will hear later 
from Wes, he tested that molecule, came back and said, ‘Look guys, this has 
got antiemetic activity’. To us, it became difficult to believe that a pure gastric 
prokinetic would have that kind of activity against such severe nausea and 
vomiting. By that time, we had access to John Fozard’s compound, MDL 72222, 
a selective 5HT3 receptor antagonist.
132 We could then go back to the ferret 
emesis model and say, ‘Look, let’s do the study. I will predict that this selective 
5HT3 receptor antagonist will take out this type of vomiting. The mechanism 
has nothing to do with D2, and nothing to do with what then became known 
as the 5HT4 receptor’.
133 I gave the compound to Wes. There are lots of little 
anecdotes in that little book that I brought with me, but the one I like is that 
that study was done late on a Friday afternoon. Wes came back from the animal 
house, which was then a little shack round the back of the building, and said, 
‘Look, these guys did not vomit’. He looked at four animals: three didn’t vomit 
at all, and one started to vomit near the end of the observation period. At that 
time, this was an utterly unprecedented result, and none of us could tell anybody 
130 See, for example, Sanger (1993): 186.
131 Dr Gareth Sanger wrote: ‘At this time, the main drugs marketed as antiemetics, acted as dopamine 
D
2
 receptor antagonists. Therefore to prevent emesis via a different receptor would have immediately 
raised the possibility of a “new” biology. See McRitchie et al. (1984): 287–301.’ Note on draft transcript, 
31 May 2007.
132 Fozard (1984b). 
133 Dumuis et al. (1989).
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until Monday. So it was a kind of nice exciting result, which we kept to ourselves 
all weekend. We then took that information, and knowing that we had all the 
competitors around us, developed our own 5HT3 receptor antagonist, which is 
granisetron or Kytril® now.134 I guess that cuts a long story short. 
During the history of that development, we had to face questions about whether 
or not 5HT3 receptor antagonists blocked the antitumour effect of cisplatin. I 
knew Beverley Weston, who then worked for Beecham, and luckily she was 
married to Ken [Harrap], and so we came along to you, Ken, and you did those 
studies to show we had no impairment of cisplatin’s antitumour activity; at 
that time a really serious issue.135 I then took the show around various oncology 
departments. I heard people say, ‘Do you believe this 5HT stuff?’ You knew 
there was no understanding of the science. We called in people to help us with 
the science, in particular Paul Andrews. I remember him coming into the labs 
saying, ‘Look, I have just been given this white powder from Glaxo to test, I 
have no idea what it is, but they want me to test it’. I took him in the lab and 
said, ‘Well, we know what it is, here is its structure and here’s our data on the 
compound’. That was ondansetron. So a lot of different, emotional stories; the 
kids who vomited their hearts out with cisplatin, everybody in tears; and then 
the doctors, on their own responsibility giving BRL 43694 (granisetron) [5HT3 
receptor antagonist] as it was then known, which stopped vomiting in its tracks 
and thus allowed chemotherapy to be effective. And then many more tears and 
emotions. These things came back to the lab as we were doing the work. We 
heard that in Japan, certain patients on the oncology ward were given Kytril®. 
They were protected and the rest of patients on the wards who hadn’t been given 
Kytril® rioted. They wanted that drug. And it was that kind of information 
that was fed back to us in the lab, ‘Look fellows, this thing does work’. 
calman: Absolutely fascinating. Are there any other comments on this 
developmental area?
mr Wesley miner: I would like to expand a little bit on what Gareth has said, 
because it was a very exciting time for us. It is one of the things that put me on 
134 Granisetron, trade name Kytril®. See PhRMA (Pharmaceutical Research and Manufacturers of America) 
(1998). See also Kytril® [www.rocheusa.com/products/kytril/ (visited 14 June 2007)].
135 Professor Ken Harrap wrote: ‘During the Beecham development of granisetron, we did some work in 
my department at the Institute of Cancer Research [Sutton], that demonstrated unequivocally that, when 
co-administered with cisplatin to tumour-bearing mice, the antitumour properties of cisplatin were not 
affected by granisetron.’ Letter to Dr Daphne Christie, 26 August 2006.
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an adrenaline high for about four or five years afterwards. It was that exciting. 
The reason it was so exciting – because I came into the whole story in the early 
1980s – is that we were hit with this huge clinical problem which Dick [Gralla] 
has alluded to, and other people have alluded to, the very severe vomiting and 
nausea. I was very naive back at that time, and said, ‘OK, here we go. Let’s 
do something about this,’ thinking we were going to solve it. We didn’t know 
quite how at that point. But everything pretty much followed how Gareth 
described it. We certainly went on with Dick’s [Gralla] work with high-dose 
metoclopramide. 
The other big thing was John Schurig’s publication on cisplatin-induced emesis 
in the ferret, and I have to give all the credit to the little ferret.136 I think ferrets 
have been alluded to as these little vomiting animals, but without the ferret, 
none of this would have got anywhere. I think this is important in this day 
and age, because we are [now] facing so many problems with [limits to] animal 
experimentation. Well, this is one area that would never have gone forward; you 
couldn’t have done it without the ferret and the animal experimentation. We 
certainly looked at the dopamine antagonist, and that actually made the emesis 
worse in the ferret. We looked at metoclopramide, and then put together what 
was happening with 5HT3 receptors. 
One other thing I would like to tell you about is with respect to the excitement 
and what I saw when I was working with the animal models. We had a period 
where we knew we were looking at 5HT3 receptors. We knew what was 
going on; we knew these drugs were good. Up until that time, the way I had 
conducted the experiments was that I dosed the animal with cisplatin and if 
you have a control animal dosed with cisplatin it takes 60 minutes before the 
cisplatin will begin to cause the animal to vomit. So I would do that, but prior 
to that I would dose with a 5HT3 antagonist, and with the 5HT3 antagonist, 
essentially the animals just would not vomit. So you wouldn’t see any vomiting 
with the animals at all. Well, while I was running these experiments, I figured, 
‘Well, I have to run a control experiment with this; I have to make sure the 
cisplatin is getting on board’. So I decided what I would do is with every four 
animals that I would be dosing, I would dose all of them with cisplatin, but 
one wouldn’t get the 5HT3 antagonist. And I would watch them all. I did this 
a couple of times and by about the third time I was getting complete inhibition 
with the 5HT3 antagonist, the animals were just not vomiting at all, but this 
poor little control animal, right on 60 minutes, bingo, right off and he began 
136 Florczyk et al. (1982).
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vomiting. This began to concern me, because I figured, ‘Well, okay, I do know 
the cisplatin is on board, but I am going to have to do something. I can’t just 
let this poor little guy go away and vomit the whole time’. At that time we 
had actually surgically prepared the animals. You cannot dose a ferret easily. 
They just will not let you do it. So I had to surgically prepare the animal with 
a little intravenous cannula and it used to be exteriorized right at the back 
of the neck. I was working on my own with the ferrets at this time, which 
Gareth alluded to. They wouldn’t even let me in the experimental areas with 
the ferrets, because nobody liked them. 
So I was in a little back ‘kitchen’, in my cell, with my four ferrets, and I had 
to think of a way of putting the little connector on the little valve at the back 
of the neck of the animal, so that I could actually get the 5HT3 antagonist on 
board while the animal was vomiting. The only way I could think of doing 
this, once the other animals had been dosed with the 5HT3 antagonist, and this 
animal had actually started vomiting, is to wait until the animal is vomiting, he 
is not going to be paying attention to my fingers. I am not going to lose fingers 
this way. So this is exactly what happened. I waited until the animal started 
vomiting. I knew the cisplatin was working at that point, and I just very nimbly 
and very quickly fastened this little connector and while the animal was actually 
right in the middle of the emetic response, I whacked in the 5HT3 antagonist, 
and within five seconds the animal was normal, completely normal. This was 
one of the most exciting things I have ever seen, and it really gave me confidence 
then that we had something big. 
Then, of course, I was stuck with the situation, how am I going to get this little 
connector off the animal, because it was now completely normal. So I decided 
what I would do. Ferrets absolutely love milk, and so I prepared a small bowl of 
milk and I put it in his pen, and the ferret ran over and I got the little connector 
off and that was it. We went on to do this on several occasions, and we videoed 
this result and it got shown to quite a number of people. But that result was that 
dramatic, and I do remember calling Paul [Andrews], and I said, ‘Paul, I think 
we really have got something here’, and he said, ‘Yes, I think you have got it’. 
And we were very pleased with that. So that’s pretty much the Beecham side of 
it, and as Gareth [Sanger] said, there’s a lot of other little tales.
sanger: I will slightly embellish Wes’ story, because that animal experiment 
Wes described was videoed; it became known as the ‘ferret video’ within our 
industry. I think that was the single most powerful message we could deliver 
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to our upper management to say, ‘Look guys, we have something here that’s 
exciting and works’. We showed that ferret video and they came on board.
But the other very interesting point I want to make, alluding to Wes’ comments 
on the necessity of animal experimentation to do this kind of work, relates to 
a seminar I gave at our local hospital on this kind of biology. It’s kind of nice 
to start off with this video, because it gets them excited, and then they start 
listening to the science (otherwise they go to sleep). You start off with the video, 
and as I showed it, half the oncology nursing staff walked out in disgust. This 
was an animal experiment – you can do it to patients, but not to animals. They 
walked out. It was quite extraordinary.
miner: One little comment, Gareth said at the end of that first day, the first 
time we did those experiments, that I came back to the lab and it was a 
Friday and all that, if truth be known he actually came over to the little place 
that I was in, popped his head around the door, and asked, ‘Did it work?’ 
It worked.
professor robert naylor: Just to add to some of these experiences, recollections 
and reminiscences. What I have found today that is really interesting is that 
all the experiments, clinical or otherwise, which have been done by chance or 
design, or could perhaps have been done in different ways, have dramatically 
affected the outcome.137 And to do many of the experiments these days would 
be difficult indeed. 
Briefly, at Bradford we have had a serious interest in neuropharmacological 
research since 1968. The Neuropharmacology Research Group was set up 
initially to investigate the actions of antischizophrenic drugs and drugs useful 
in the treatment of neurological disease. By the mid-1970s we had built strong 
collaborative research programmes with many pharmaceutical companies. A H 
Robins in Richmond, Virginia, was one such company who were investigating 
dopamine receptor antagonists, which has already been discussed.138
Dr Lawrence (Larry) Sancilio and colleagues at A H Robins Company, were 
attempting to dissociate the dopamine receptor blockade from extrapyramidal 
side-effects and antiemetic potential. It was clear to them that you could block 
137 This is a recurrent theme that has come up in other Witness Seminars. See, for example, Zallen et al. 
(2004): 30; Tovey (1992).
138 See pages 52–3. 
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emesis induced by cisplatin in dogs without dopamine receptor blockade; 
zacopride and dazopride were two such agents.139 
We determined that zacopride was a particularly potent antiemetic agent against 
cisplatin in the ferret model of emesis. But neither we nor colleagues at A H 
Robins were aware of the antiemetic mechanism of action of zacopride.140 
In Bradford we were following a similar hypothesis. Using a recently discovered 
5HT M receptor antagonist, ICS 205-930 (tropisetron), obtained from Sandoz, 
we investigated the ability of this agent to facilitate gastric emptying following 
injection into the guinea-pig hypothalamus. The importance of this observation 
was our additional finding that ICS 205-930 potently blocked cisplatin-induced 
emesis in the ferret.141 
I reasoned that if this hypothesis (the facilitation of gastric emptying) was 
correct, then zacopride and ICS 205-930 might facilitate intestinal transit in 
man. In the noble tradition of a nineteenth century physician,142 I took the 
drugs, but neither appeared to facilitate gut activity. Indeed, with n=1, the trial 
suggested a reduced gut movement. The hypothesis looked less hopeful.
On informing Sandoz of the antiemetic action of ICS 205-930, the company 
remained unimpressed or disinterested. But during this period, Professor Brenda 
139 Dr David Tattersall wrote: ‘At the time the 5HT3 receptor antagonists were being examined at Bradford 
it was felt that these agents would be clinically useful for treating a variety of psychiatric and neurological 
diseases. Unfortunately, the only clinical utility of these compounds proved to be as antiemetics. This was 
similarly seen with the Substance P (NK1) receptor antagonists, which were hailed as treatments for anxiety, 
depression and pain, as well as antiemetics. Thus far, the only approved use of NK1 receptor antagonists 
has been as antiemetics. I think it is important to make this point because the market for antiemetic agents 
still remains poor. As such, it is a much less attractive target for the pharmaceutical industry than other 
indications that have a much greater potential market. It has been estimated that a drug costs around $800 
million to develop (not including the cost of compounds that do not make it to the clinic).’ Note on draft 
transcript, 31 August 2006. 
140 Professor Robert Naylor wrote: ‘At the Robins Company, David Johnson, Larry Sancilio, Herb Alphin 
and colleagues were investigating the actions of zacopride and related agents to enhance isolated gut smooth 
muscle cell contractions. This might be envisaged to facilitate the propulsion of gut contents in the anal 
direction, to facilitate an “antiemetic” effect.’ E-mail to Dr Daphne Christie, 14 October 2006. See, for 
example, Sancilio et al. (1991).
141 Dr David Tattersall wrote: ‘The original finding of antiemetic activity with ICS 205-930 in the Bradford 
laboratory was published in Costall et al. (1986).’ Note on draft transcript, 7 February 2007. See also Gamse 
(1990).
142 See, for example, Altman (1987); Kerridge (2003). See also Reynolds and Tansey (2001): 27.
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Costall and her neuropharmacology team at Bradford had been working with 
Dr Mike Tyers and Dr Dave Fortune at Glaxo on a series of novel 5HT receptor 
ligands in behavioural models. One such compound, named GR 38032F (later 
ondansetron, or Zofran®) and described as a selective 5HT3 receptor antagonist, 
was tested in the cisplatin model of emesis in the ferret.143 It abolished emesis. 
Glaxo were informed and were interested; the rest is history.144
Following its clinical introduction, Dr Gralla and colleagues revealed that 
ondansetron was a less effective antiemetic in what was described as the ‘delayed 
phase’. This prompted further ferret studies in both an acute and delayed phase 
by my colleague Dr John Rudd in Bradford and by others. The 5HT3 receptor 
antagonists were shown to be less effective in the delayed phase. The importance 
of this observation is as follows. Would Glaxo management have developed 
ondansetron if the drug had been shown to be only moderately effective over 
a three-day period? It was a good reason not to persevere, as there were many 
other drugs in the Glaxo pipeline. 
Personally, I remained quietly convinced that the 5HT3 receptor antagonists 
had genuine benefits, and not just as a result of carefully designed clinical trials. 
As a laboratory scientist I received letters from cancer patients thanking us for 
making their treatment more acceptable. This is surely almost unheard of? 
Their correspondence made for a good day and a very good year. We were all 
grateful for having the opportunity to make a difference. That is, all except 
my local health authority. The headlines in my local newspaper the Bradford 
Telegraph and Argus announced that the cost of the new antiemetic drugs had 
bankrupted the local health authority and that a Professor Naylor working at 
the local university was to blame.
Brock: Moving on from this I want to give a clinical paediatric story. I was part 
of a group called the Paediatric Oncology Group of Benelux (OPB); I worked 
in Louvain in Belgium. The only publication that came out of this group 
was a randomized study on the induction dose of ondansetron; a 5 mg/m2 or 
143 Stables et al. (1987).
144 Professor Robert Naylor wrote: ‘But in retrospect, the clinical development of ondansetron to achieve 
global success in the treatment of emesis in the cancer patient probably retained a modicum of good luck 
in the preclinical development. In our ferret model of cisplatin-induced emesis the experiment was of four 
hours duration, believing that authorization by the Home Office to perform the experiments would have 
been compromised if we had requested a longer exposure of the animal to a moderately severe procedure.’ 
E-mail to Dr Daphne Christie, 14 October 2006.
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10 mg/m2, with Glaxo’s support, which I then published.145 One of the reasons 
that we started this was that we were desperately keen to get this drug for our 
children on the ward, but it was expensive. And in young children we had a lot 
of problems. We couldn’t increase the dose of metoclopramide; once you go 
above to 1 mg/kg per dose, or to 1.5, we were getting a lot of dystonic reactions 
and some of them were in the throat, and really quite frightening and nasty, 
and the nurses wouldn’t let us do it. So we decided to get this study going, a 
randomized study, where the children would either get 5 mg/m2, which we 
knew worked, or 10 mg/m2 which we hoped might work a bit better. But what 
it meant was that all our kids got ondansetron and we got it for free. I had a 
wonderful time doing the study with Glaxo, because they took me everywhere 
and we presented the work everywhere. We used to do the ward round every 
single day with our professor who was very, very strict. At 9 a.m. we would all go 
round, and every single child would be on their bed – you can’t do a ward round 
like that any more – but they would all be there with their cardboard kidney 
bowls, vomiting, and we would do every single ward round, every morning, 
every room, and it would smell bad, and we would feel bad, and the children 
wouldn’t be able to tell us anything because they were just throwing up all over 
the place. Then once we started with ondansetron nobody was vomiting any 
more, and then in the cafeteria, because in Belgium the food is good, they would 
be served steak and fish, and chocolate mousse; but they couldn’t even have the 
food trays in the room before ondansetron. But afterwards, the kitchen staff 
would come running up to me and they would say, ‘Professor Brock, Professor 
Brock, what’s going on? All the oncology patients are ordering food, they want 
chocolate mousse, we are coming and fetching the trays and the food has been 
eaten, and it is not the parents who are eating the food, because the parents also 
get their own tray’. To me, that was a wonderful watershed, when we did ward 
rounds not only were they not vomiting, but they actually were ordering food 
and eating it. 
I agree entirely about the delayed emesis, because I then did a study on serotonin 
metabolites in the urine, and serotonin is released in the 24 hours after cisplatin 
and bang, it goes. I have been trying to tell people for years not to waste the 
money on ondansetron on days two to five, but use something else. But it is 
finally getting through because we are so tight for money that they are beginning 
to cut back.
145 Brock et al. (1996).
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naylor: Cost has always been a real problem with this particular group of 
drugs.146 For example, there have been up to 30 people working in Bradford 
in neuropharmacology research over the last 35 years. You know that many 
frequently work 12–14 hours a day; thousands and thousands of hours go into 
their studies.147 
Yet, following the headline in my local newspaper (the Bradford Telegraph and 
Argus) that I had bankrupted Bradford Health Authority with the expense of the 
new antiemetic medication, I failed to respond with a rebuttal. And a chance to 
refute a silly allegation and enhance the scientific enterprise was lost.
calman: My particular incident was with methotrexate, when we were using 
higher and higher and higher doses, and the drug rep from methotrexate 
actually won a holiday for selling the most methotrexate. He had a fortnight in 
Barbados, and our health authority was almost bankrupt. 
andrews: Can I make one point about the cost? I agree completely about 
the food on the wards, which people did start to comment about, but also 
because when these drugs first came out, they were very expensive, relative 
to metoclopramide – metoclopramide and dexamethasone were very cheap 
– and many of the companies were very concerned that the people were not 
getting the compounds because of the cost. I think it was Glaxo who actually 
calculated the cost of a vomit for a patient, how much the bowl cost, how much 
cleaning-up cost, and factored that into these pharmacoeconomic models, and 
I think the 5HT3 receptor antagonists were the first examples of drugs where 
pharmacoeconomics played a major role in the whole marketing package.148 
So I think they really did change the paradigm, because the other point is that 
at the time when the companies started, if you did a survey on how much the 
antiemetic market was going to be worth, it was almost nothing, so it wasn’t 
an area to go into for the money, whereas, I think, now worldwide it’s over $1 
146 Professor Robert Naylor wrote: ‘Clearly scientists and clinical staff are not responsible for the setting of 
the cost of drugs. But I am not sure that as scientists we have fully pulled our weight.’ E-mail to Dr Daphne 
Christie, 14 October 2006.
147 Professor Robert Naylor wrote: ‘For example, one Boxing Day [the day following Christmas Day] a 
few years ago, the Chancellor of the University of Bradford, an influential business man, was visiting the 
university to encourage his troops. That he found many research pharmacologists working in the laboratories 
provided him with dinner table conversation of hard-working staff in his university for years to come.’ 
E-mail to Dr Daphne Christie, 14 October 2006.
148 pages 67–8.
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billion and most of that is in the 5HT3 antagonists, so that set the basis now for 
encouraging people to go and look for antiemetics, because they can see that 
there’s a market if you get something better. I think it shifted the paradigm on 
antiemetic research at the time.
professor ian Judson: I wanted to add two or three observations in relation to 
this. Obviously, as a medical oncologist, I can only concur that when we first 
started to treat patients with these drugs, to see patients eating their breakfast or 
dinner while doing a ward round, was astonishing, when previously they would 
simply be sedated and still being sick. 
I vividly remember the ferret video we saw [see page 56], when together with 
Ken [Harrap], we were looking at the possibility of exploring these drugs in a 
ferret model, and in relation to the platinum development story. But I wanted 
to extend the observation, after what Ken was saying, in terms of the onward 
development beyond carboplatin. When we started, when Ken’s group started to 
develop an orally bioavailable platinum complex, that was only possible because 
of the 5HT3 antagonists. Not that JM216, the drug that finally went into the 
clinic via the oral route, was particularly emetic, it was probably comparable 
with carboplatin, but without these drugs it would have been an idiotic thing 
to do. As it was, people still said it was a laughable concept, but without these 
drugs, it would have been an impossible concept. 
sanger: I have got one very small point to make. Bob’s [Naylor] comments 
about the letters he received reminded me of this. I only received one letter 
and that was from the antivivisectionists, and following that I spent three 
months searching for bombs under my car, following police security advice. 
Very different experiences.
miner: A real quick comment on what Bob [Naylor] was saying before about the 
gut motility and prokinetic effects of these drugs. I think it is important when 
we look back on it now – if anybody ever decides to reinvestigate this whole 
work – when Gareth [Sanger] and I were looking at the drugs, we certainly 
looked at renzapride, which is quite a reasonable 5HT3 antagonist, but it does 
not completely block the emesis that you see in the ferret. I have always had a 
feeling, and Paul [Andrews] and I have talked about this before, that the actual 
prokinetic effects, the 5HT4 agonist effect, probably detracts a little bit from 
the 5HT3 antagonist activity. We just need to clarify that a little bit if we are 
going forward.
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grahame-smith: Despite what we have heard there is something that still 
confuses me and that is that we don’t have a clear mechanism of action of 
the 5HT3 antagonists. By that I mean: where are they working, how are they 
working and what is the mechanism by which cisplatin causes vomiting? Some 
people may think they know the answer to those things, but I certainly don’t 
know the answers in terms of precise molecular mechanisms. 
I think it is unfair to talk about pure serendipity, because although, looking 
back, the 5HT3 antagonists were developed serendipitously, there was the high-
dose metoclopramide pointer. Nor was the process entirely intuitive – logical 
steps were followed, and one can see that with hindsight – but we didn’t know 
the molecular mechanism of action of cisplatin that caused emesis in order to be 
able to target a molecular event on the way with a compound. We didn’t have 
that, and I don’t think we do now.
Dr David Tattersall: I was Robert Naylor’s PhD student and I think you have 
brought up a very important point. I was also involved in the Substance P (NK1) 
receptor antagonists, and we spent many years trying to determine molecular 
interactions for the mechanisms of action of the NK1 receptor antagonists. If 
we had done the same with the 5HT3 receptor antagonists it would have taken 
ten years, so the original observation, the original published observation for 
5HT3 receptor antagonists was about 1985. The compounds were in the clinic; 
indeed a number of pharmaceutical companies had compounds in the clinic, 
very very rapidly. With the NK1s we couldn’t do that, because we had to show 
more mechanism of action. I think it was purely serendipitous that we didn’t 
at that time with the 5HT3 antagonists. So, for instance, we had very little 
pharmacokinetics. In 1991, approximately 40 per cent of compounds that were 
taken into the clinic failed due to poor pharmacokinetics in humans. By 2001 
that had been reduced to 10 per cent, so we’ve solved the pharmacokinetics. 
We had efficacy in a model that we believed to be predictive, and this was an 
unusual species, it wasn’t something that had been used very long, less than 10 
years. We didn’t obtain toxicity information with the NK1s in ferrets. It was felt 
that it wasn’t going to be predictive of what happened in humans, because there 
was no background data. So I think that it was entirely fortuitous that we didn’t 
pursue too much of a mechanism of action. That was going on, however, in a 
number of academic institutions at the time. 
Dr John rudd: I also came from Bradford where Robert [Naylor] was my 
supervisor. For me things started off in 1988 and at that time the first information 
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I read was a review by Paul [Andrews], who hasn’t really had that much to say.149 
Everybody was searching for a mechanism of action, and within Bradford, and 
within other laboratories around the world, we were all looking, and there were 
new technologies coming along, we had autoradiography, we had high pressure 
liquid chromatography (HPLC), showing changes in transmitter levels, and we 
could see where the 5HT3 receptors were. So it was quite exciting. In those days 
it was a privilege to be in the laboratory, because in Robert’s laboratory you 
could do anything you wanted. If you wanted to try something, you would 
go to the cupboard, open it, and it was full of drugs. Today I found out that 
Robert has taken one or two of them himself.150 But it was full of drugs, and 
you were able to do any type of experiment that you wanted, and in a way you 
had this freedom to do it. When I came along, ondansetron (GR38032), well, 
it was old news in 1988,151 and we thought we should look for responses that 
weren’t blocked by ondansetron. And then we started to read about the problem 
with delayed emesis, and we started to understand the current animal model, 
this simple cisplatin (10 mg/kg)-induced emesis model wasn’t going to produce 
the answer.152 And how do you make a step from acute emesis, to an acute and 
delayed-emesis model? I think it’s by talking to the very people that are in this 
room. So what was I able to do as a student? I was able to go to every British 
Pharmacological Society meeting I could, I could travel around the world and 
talk to different people, and basically that’s how you make a discovery. So in 
the early 1990s, a Japanese group was looking at cisplatin in pigeons, and had 
149 Dr John Rudd wrote: ‘In actual fact, Professor Paul Andrews had pulled together many key scientists 
working in the emesis research field, providing modern ideas for emesis control, many of which appeared 
in his original review in the 1988 September issue of Trends in Pharmacological Sciences [Andrews et al. 
(1988)].’ E-mail to Dr Daphne Christie, 16 November 2006.
150 See page 58.
151 Dr John Rudd wrote: ‘Primarily because 5HT3 receptor antagonists were already showing promise to 
reduce cisplatin-induced nausea and emesis in patients.’ E-mail to Dr Daphne Christie, 16 November 
2006.
152 Dr John Rudd wrote: ‘The original cisplatin (10 mg/kg)-induced emesis 4–6-h ferret model is sensitive 
to 5HT3 receptor antagonists, but relatively insensitive to dexamethasone; even their combination fails to 
produce reliable additive effects to reduce retching and vomiting. However, combinations of glucocorticoids 
with other antiemetics were effective to reduce nausea and emesis in man. Therefore, we set out to find new 
emesis models capable of detecting the antiemetic activity of dexamethasone. The key experiments were 
funded by Glaxo Group Research, with input from Drs K T Bunce and C C Jordan.’ E-mail to Dr Daphne 
Christie, 16 November 2006.
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interesting data,153 so we take note of that. One of the most important things I 
heard was a conversation from Robert after he came back from a meeting. He 
had spoken to Gareth [Sanger], talking about a study, again done by a Japanese 
group, in the dog with cisplatin, whereas in that particular experiment, if you 
prevented the dogs from being sick, and then you fed them 20 hours later, 
they would vomit.154 But the control animals that had vomited at the start of 
the experiment did not vomit again when subsequently fed at 20 hours. So it 
seemed to me that somehow our ferrets were really vomiting too much, and we 
should try to do something about it. And Glaxo were still interested in this at 
the time, and had a meeting [in Bradford] and they wanted us to go forward at 
the 10-mg dose over 24 hours and see whether or not we could see a delayed 
phase.155 At the time, bringing together all the things from Richard [Gralla] and 
around the world, and knowing what delayed emesis was, I said to myself, ‘Well, 
why don’t we just do it properly, do a proper dose–response again (3–10 mg/
kg, i.p.), start at the beginning, and use a three-day period. And that’s exactly 
what we did, and when I think about what I did, and what Wes is talking about, 
Wes had got a very nice laboratory at the bottom of his building, that was very 
nice. Robert put me at the top of my building, and I had to go out across the 
roof, in the snow, in the rain, into my little room, where nobody would come 
to visit me. 
The other thing that I should share with you is that when you do acute and 
delayed emesis experiments, you are literally sleeping at work. So I spent three 
days or so at work, and I would sleep on the office floor. Going to work at night 
I wouldn’t switch on the lights, because I didn’t want anybody to know that I 
was there, because you would have stories of people literally having their arms 
153 Dr John Rudd wrote: ‘An abstract showing the temporal profile of emesis induced by cisplatin (3 mg/
kg, i.p.) in the pigeon was shown at a Serotonin Club meeting in Houston in 1992 [Uchiyama and Suzuki 
(1992): 62]. Cisplatin induced a “biphasic” response, but some 5HT3 receptor antagonists themselves 
induce emesis in pigeons, making it difficult to rationalize the data with the clinical situation.’ E-mail to Dr 
Daphne Christie, 16 November 2006.
154 Dr John Rudd wrote: ‘The original dog study was conducted by Fukuda and co-workers [Fukuda 
et al. (1991)]. A similar study was subsequently performed using an identical protocol with DAT-582 
[(6R)-(-)-N-[1-methyl-4-(3-methylbenzyl)hexahydro-1H-1,4-diazepin-6-yl]-1H-indazole-3-carboxamide 
dihydrochloride] [Yoshida et al. (1992)]. We quickly performed our own experiments on the ferret (June 
1992), but did not see emesis in ondansetron-protected animals when they were fed at 20 h.’ E-mail to Dr 
Daphne Christie, 16 November 2006.
155 Dr John Rudd wrote: ‘Those present at the meeting in Bradford were Drs D J Twissell, C Bountra, J A 
Rudd and Professor R J Naylor.’ E-mail to Dr Daphne Christie, 16 November 2006.
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broken. So I used to have to learn my way around the laboratory, because we 
didn’t have very good security.156 I think the average age of the security guards 
was 50-something. These are the types of things that you had to go through. 
We went on to develop this model of cisplatin-induced emesis with an interest 
originally in dexamethasone, to try to look for a model that could detect the 
antiemetic activity of dexamethasone, and from there we went on to look at the 
NK1 receptor antagonist.
157 
I remember having big chocolate bars and coffee just to keep me awake and, I 
guess, listening to your stories has been quite a privilege. So what can I say? I 
remember seeing Robert. I would be in my laboratory at 11 pm. He would be in 
his tuxedo, going somewhere nice, and I am still, to this day, doing these types 
of experiments, and I have still not put on a tuxedo.
calman: I am conscious that we have one other area to cover, so could we make 
this the last couple of comments.
gralla: We have had some wonderful stories about the controlled emesis, exciting 
research from the clinical to the lab, and back to the clinical, but I think we may 
be giving a mis-impression, and I think it’s very important that we have heard 
John Rudd and David Tattersall speak. First of all, there’s tremendous advantage 
and tremendous value to the animal models, but there are major limitations: 
(1) corticosteroids are excellent in humans, not so good in the animal models; 
(2) you can completely shut off the emesis with many of these antiemetics in 
animal models, but you cannot do that in humans. The story is much different 
in humans than in animals, in terms of the degree of control. We do not have 
anything approaching 100 per cent control, and we should not walk away 
saying that we do. We have a wonderful change that all of us like to look on 
the bright side, from 100 per cent of patients being sick, to a small majority of 
patients being sick now. In other words, the 5HT3 antagonists are an advantage 
over metoclopramide, in terms of fewer side-effects, dystonic reactions and 
greater convenience, but as far as the antiemetic control is concerned, only a 
small advantage. That greater convenience contributed to the fact that they 
156 Dr John Rudd wrote: ‘Anti-vivisection activists were a serious concern to most scientists working with 
animals in the UK in the 1990s.’ E-mail to Dr Daphne Christie, 16 November 2006.
157 Dr John Rudd wrote: ‘The new cisplatin (5 mg/kg, i.p.)-induced acute and delayed emesis model was 
sensitive to 5HT3 receptor antagonists and glucocorticoids. The model subsequently revealed the potential 
of NK1 receptor antagonists to treat delayed emesis [Rudd et al. (1996)].’ E-mail to Dr Daphne Christie, 
16 November 2006.
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can be easily used by most physicians, a single dose is as good as multiple, and 
what we didn’t know in the beginning, that they are perfect for paediatrics, 
because they don’t have dystonic reactions. A study published a few months ago, 
an extraordinarily well-done study, showed that the combination of a 5HT3 
antagonist and dexamethasone after four cycles of chemotherapy in women 
with breast cancer who were previously untreated, were getting it mainly for 
adjuvant purposes, only 39 per cent were completely free of emesis during the 
entire treatment.158 So we have made enormous progress, but we still have a long 
way to go. 
The problems with industry are a plus and a minus; the plus is that without 
industry we would not have the 5HT3 antagonists, so we should be extremely 
grateful. But then when the marketing department takes over, they wish to 
believe that serotonin is the only mechanism that causes emesis. This was a 
grave mistake, at which point I became not too popular in a couple of these 
companies, by saying, ‘OK, this is an important pathway, but not enough’. That 
is where we have some wonderful studies that David Tattersall has published, 
looking at NK1 antagonists, that many others in this room have looked at, and 
these have helped us go forward.159 These have helped us understand, as John 
said, about the delayed emesis and about the NK1. So we have to recognize that 
we have a long way to go. We have taken a big step, but we oncologists need to 
reach the point where we can face every patient and say, ‘Emesis is not likely to 
be a big problem for you’. We have taken about four steps, and we have three 
or four more. It is wonderful that 80+ per cent of patients now treated with 
NK1 antagonists can be completely protected against acute emesis, and that 
60–70 per cent can be completely protected against delayed emesis. What we 
have are problems that I heard over here before, the fact that in the 1980s, we 
had patients, all of them, with emesis. That was not necessary, there were drugs 
that would have done a much better job and that were available at that time, 
but they were not employed. We have a problem of effectiveness and efficacy. 
The efficacy and the effectiveness level is less, which is what happens in the 
real world. Getting the word out is important. Part of this is the smokescreen 
created by the economic problem. The 5HT3 antagonists are some of the most 
cost-effective drugs, or probably the most cost-effective drugs in oncology. They 
prevent hospitalization. You don’t have to prevent very many hospitalizations 
to make them economically sound. They are a dominant strategy for many 
158 Perez (1998).
159 See, for example, Tattersall et al. (1993).
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patients, again because they allow us to de-hospitalize patients. I must say, in 
the UK people have been slow to de-hospitalize patients. They could save a lot 
of money, but unfortunately the expense comes from the same pair of pants, but 
a different pocket in the same pair of pants. So it’s necessary to look at all these 
aspects, because patients should not be prevented from getting these drugs, 
which are inexpensive, compared with many oncological products that work 
only marginally, because of incorrect economic evaluation. But we as clinicians, 
and as basic scientists, should not also rest on our laurels; we have a long way 
to go yet before everybody is protected. We have made giant steps, but there’s 
still a distance to go. 
Williams: One of the things that strikes me as a molecular biologist away from 
the immediate clinical field, is that if you go to a conference on platinum, 
where there are chemists studying in great detail the action of platinum, there is 
hardly any paper which does not deal with platinum and DNA. The reason for 
that is that I don’t think it has ever got through to the ordinary biochemist that 
you have a lot of problems about the toxicity. So they are not interested in this 
problem of toxicity, which obviously is absolutely critical to the use of the drug. 
It seems to me that some stimulus is needed from the medical community, down 
to the research community at the molecular level, because we have techniques 
now where you should be able to follow platinum atoms, wherever they go, 
and see what the targets they are hitting are. So why is there such a problem 
with platinum? Why don’t we know the background mechanism? There’s 
nobody that I know working on it. They don’t study the protein’s interaction 
in platinum at all any more, and I think that’s a great shame because we know 
there are several other toxic problems, and they are not being tackled by the 
molecular biologists. If you knew where the platinum went, then you might 
have a different route to preventing its action in the wrong places, rather than 
hitting a completely different target which is something to do with emesis. So 
instead of stopping emesis, find out why it ever started.
andrews: The hypothesis, I think, that most of us accept of how the platinum 
works, in the acute phase, is that it acts on the enterochromaffin cells in the 
upper part of the gastrointestinal tract. For some reason, they seem to be 
particularly sensitive to the effects of cisplatin and indeed other cytotoxic drugs 
with a different action. One of the hypotheses which has reasonable evidence 
is that there’s a generation of free radicals within those cells. That causes an 
influx of calcium ions, which then leads to normal exocytosis of 5HT from the 
granules; it is not the cells being destroyed and breaking open. There are a lot of 
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mistakes in the literature. It is not the cells that are breaking open, because it is 
far too quick for that. It is normal exocytosis of 5HT-containing granules that’s 
triggered, and the 5HT then acts on the 5HT3 receptor, which is located on the 
vagal terminals peripherally, it’s not systemically released 5HT; it’s very much 
locally released. There may be some effect within the central nervous system, but 
the bulk of the evidence from the ferret studies is for a peripheral effect within 
the gastrointestinal tract. So I agree with you. In fact a number of us, including 
Gareth and I, wrote in a 1988 review about why the enterochromaffin cells are 
so sensitive to the substance.160 
The other thing that is curious is that 80–90 per cent of the 5HT in the 
body lines the gastrointestinal tract. It is lining the mucosa, it is not in the 
neurones. So we have hypothesized that maybe you could predict emetic 
efficacy for cytotoxics by looking at the ease with which they release 5HT from 
enterochromaffin cells, but nobody has ever done that, because there’s not a 
very good enterochromaffin cell model around to study. But it is very curious 
why those cells should be so sensitive.
calman: I think it’s really nice to end this session with a question, and that says 
that this is not resolved, and there are still some very fundamental things to 
be done.
Brock: Although the emesis issue has been terribly important, and I agree entirely 
that it needs to be taken forward, I wanted to come back to the fact that for us, 
of course, as paediatric oncologists, the really important toxicity is the permanent 
toxicity. The real problem there is this battle with the effect of the platinum on 
the DNA and the efficacy of the platinum on the tumour and the effect of the 
platinum on the healthy cells, which then causes the toxicity. But I want to be a 
little bit encouraging, and probably that’s true that we do try to look at the good 
side, but if you are an oncologist you have to. This year the Royal National Institute 
of the Deaf has really taken on the challenge of trying to get the pharmaceutical 
firms to search for new chemoprotectants. They had a very big press conference 
just a few months ago that I was involved in, to try to put forward the fact that 
there’s probably $1.4 billion worth of industry out there to get the right drug to 
prevent the toxicity, particularly to the ear. I got involved and was invited out to 
the USA last year to look at Professor Ed Neuwelt’s work, who is a neurosurgeon, 
an amazing man from Portland, Oregon, who has been doing a lot of work on 
sodium thiosulphate. Professor Neuwelt has been doing work in animal models, 
160 Andrews et al. (1988). See also Andrews and Sanger (eds) (1993); Racké et al. (1995): 18.
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xenograph mouse models, and cell lines, in STS [sodium thiosulfate], the antidote 
for cyanide, which is found in every single hospital in the world, and is cheap. 
He started looking into this because he uses carboplatin in blood–brain barrier 
disruption for brain tumours, and when you give carboplatin through blood–
brain barrier disruption, you get very severe toxicity.161 One of his patients was a 
professor at the university – you don’t like to give radiotherapy to a patient over the 
age of 60, because they develop dementia – she accepted the blood–brain barrier 
disruption programme, giving intra-arterial carboplatin after mannitol, and she 
became deaf. It was her husband who discovered the STS, and that triggered the 
programme into looking at STS, but I think they have got a balance now between 
the timing of the platinum and the delayed timing of the STS, and are looking at 
it very carefully in the hope that we will actually prevent the permanent toxicity 
of platinum, which is so serious, particularly for the children.
calman: It is interesting looking back. I began in 1974, I had no staff, no office, 
no beds, no telephone, no typewriter, and it really was amazing how we all had 
to deal with that, and that’s the way it was. 
I mentioned the issues of sperm storage, and I think that’s quite an interesting 
area for comments. 
Maybe we should also mention the issue of support groups, and part of the 
answer that I found almost immediately, indeed when I went to the Memorial 
Sloan-Kettering,162 I noticed just how involved the groups were there. I set up 
my own little set of groups in Scotland, called ‘Tak Tent’, which is the old 
Scots phrase for ‘Take Care’ and in a sense it predated ‘Backup’, because Vicky 
Clement-Jones came to see me in terms of how this might develop.163 The key 
was that individual patient groups were able to help other patients. For example, 
we had someone who worked in a benefit office and who wrote on how to 
get benefits appropriately, and others, particularly those who had experienced 
sickness or hair loss, who also wrote for other patients. We wanted to encourage 
that, and this was quite important for me. We also had some trouble with health 
and safety because of the amount, and the way in which drugs were being 
administered. They were generally made up in a small room close to the patient 
161 Neuwelt et al. (1998).
162 Memorial Sloan-Kettering Cancer Center, NY City, NY. See note 82.
163 Dr Vicky Clement-Jones founded ‘Cancerbackup’ in 1985. The charity offers high quality information 
and support to people with cancer and to their families and friends. See www.christie.nhs.uk/patients/
infocentre/default.aspx (visited 3 May 2007).
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and in drawing up the correct amount excess drug was occasionally pumped 
into the air. This could not be seen with platinum, but with adriamycin the red 
colour was visible on the wall. 
Some of the most interesting things happened in a lift. I worked on the seventh floor 
of Gartnaval General Hospital, Glasgow, and on one occasion someone had been 
at the outpatient clinic and had been given a fairly large dose of metoclopramide 
and began to become quite dystonic on the way up in the lift. Fortunately with 
the aid of a colleague we were able to get him out and deal with it quickly. And the 
second, and this was a really important one, was when we began to treat young 
men with testicular teratomas. I went up in the lift from the clinic with a young 
man and the lift was quite full. He began to ask me what his blood levels were and 
what his X-rays were like. I had his X-rays in the lift, so we had a look at it, and I 
could see the horror from the rest of the medical staff in the lift who felt, I think, 
that this was not the way to talk to patients in this hospital. This was a remarkable 
way of showing just how powerful it was to involve patients. 
These are a few things to get you talking and I hope at some point our colleagues 
at the back of the room might just say a word or two of what it felt like from the 
patients’ perspective. Comments and other consequences of using cisplatin?
mrs Brenda reynolds:164 My daughter, Julie, was taken into hospital on 12 May 
1981 – she didn’t know, she was poorly the day before, which was the Monday. 
The local doctor came to visit and said, ‘I think your daughter has got a Wilm’s 
tumour’. Well, I stood in my kitchen dumbfounded. Never having heard of 
a child having tumours, I didn’t really associate a tumour with cancer, to be 
perfectly honest. He came back at night, at 10 pm, and said, ‘Can you be at 
Great Ormond Street, London, at 10 am?’ Myself, Julie and a good friend of 
mine, packed a bag, got in my old car, and drove down from Cambridge. We 
hadn’t a clue where we were going, and we went home eight weeks later. We had 
no anti-sickness drugs, and I think if I had known or heard what all you have 
said today, I don’t think I would have, you know, all the experiments and how 
it started, I think I would have been more frightened today than I was then. 
Really. But I was very lucky. 
We went into hospital on the Tuesday, met a Dr Jon Pritchard165 on that day, 
they did some tests, they didn’t really hold out a lot of hope for her. They 
164 Mother of Julie [Wenn], a patient aged eight, treated with cisplatinum as a child in 1981.
165 See biographical note on page 102.
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didn’t think she would be coming home, really. I think it was about a 1 per 
cent chance at that time, I am not quite sure, but it was very, very small. 
On the Friday they operated. She had a double ovarian tumour and also she 
had tumours on her lungs, and at eight-years-old, well, that was quite scary. 
But they took it out, they didn’t know whether she would come back from 
theatre all right, but she did, she couldn’t understand why she had gone into 
hospital feeling all right, and then felt desperately ill. All she wanted to do 
was go home. The hospital started her treatment: cisplatin, bleomycin and 
vinblastine, that was the combination. We had friends that came down to 
visit, and she used to cry, and I mean cry, and say, ‘Please don’t let them do it 
to me, please don’t let them do it to me’. Neighbours and friends used to say, 
‘All right, Julie?’ I used to say, ‘Out. Please go out when they come to do the 
treatment.’ Because you had to be cruel to be kind. Once the drugs went in, 
she used to watch the clock. Like you were saying with the ferrets, you could 
time it to exactly when she was going to start to be sick. We used to have to 
stay in there. I hear about people now who go in for the day for treatment and 
come home. But you used to have to spend seven days in there. And then we 
used to come home on the train, spend most of the time in the toilet, because 
she was still being sick. It’s very different now, but she came through it. It is 
now 25 years ago, 12 May 1981, and she has two beautiful children, which 
she never thought she would have, because they thought the treatment would 
cause permanent infertility. But they didn’t know what would happen with 
children, because they hadn’t had any that had grown up. But she was told 
at the age of eight that she more than likely wouldn’t have children. I didn’t 
agree with it, but Dr Pritchard was right. She grew up knowing the worst, so 
she never knew no different.
calman: Thank you very much. I know how very difficult this kind of experience 
is, and we are very grateful to you for coming.
Bagshawe: Can I raise the subject of long-term sequelae to cisplatinum? It seems 
to have two components: one is the possible effects of renal damage which 
occurs despite the hydration that takes place in its administration, and one 
generally sees a fall in the creatinine clearance [glomerular filtration rate] in 
patients receiving platinum. 
The other aspect, of course, is the question of secondary tumours. As far as I 
know, there hasn’t been any data published on the development of hypertension 
in patients who receive cisplatin, at least I don’t know of any. But I do know that 
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there is a high incidence that will be reported in the next year or so, of patients 
who have had cisplatin and who are developing systemic hypertension. 
The secondary tumour situation, of course, is much more difficult, because 
the drugs are usually given in combination. But it’s very important, I think, 
that where patients who had cisplatin with vinblastine and bleomycin in the 
testicular tumours, for instance, that those data should continue to be updated, 
because we found with the gestational tumours when we reviewed them in 
1985 that the expected number of tumours in that group, and it covered some 
3500 patient years, only two tumours were reported at that time. Ten years later, 
when the number of patient years was 15 000 odd, the incidence of secondary 
tumours was higher than expected. I think there were 37 tumours, whereas 24.5 
would be expected in that particular group. So it is very important that there 
should be a collection of data from these patients who have received cisplatin, 
without the complications introduced by other drugs, particularly of etoposide, 
which we know has a risk of secondary tumours.166 With patients who had 
cisplatin and etoposide for testicular tumours, there was a review of the data 
from Charing Cross and the London Hospital about 10 years ago, that showed 
that the relative risk of secondary leukaemias, was 150-fold.167 There were six 
acute leukaemias diagnosed, when only two were expected in that group. So 
the business of collecting data as clean as one can get it, seems to me to be 
very important.
calman: May I just emphasize that, with another little hat that I wear? The 
importance of long-term data collection, as sometimes is happening, the 
fragmentation of a thing called the NHS, may actually limit this, and I hope 
that particularly in this area, we will be able to continue to collect good data, 
because that’s the kind of information that we actually need.
Brock: I would like to strongly endorse that and I think that in that sense 
perhaps paediatrics has led the field. Dr Gill Levitt has very strongly built up 
the late effects at Great Ormond Street, London, and the average age of follow-
up now is about 35 years, so we do have records of the secondary incidences 
of cancer.168 In fact, with cisplatin it is pretty low, which is encouraging; it is 
high in the brain tumours, but is relatively low in the solid tumours. The renal 
function problems are protein and magnesium loss. But what is encouraging in 
166 Rustin et al. (1996).
167 Boschoff et al. (1995).
168 See, for example, Taylor et al. (2004). See also Cavalli (1982). 
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this area is that Gill Levitt has just been chosen as chairman of a group to lead 
the late effects study also in the adults and try to bring it together, and I think a 
lot of the international studies are making it mandatory that late effects 10-year 
follow-up is being done, and further on.
calman: I have no concerns about the clinical staff wanting to do this; I am 
concerned that systems should be available to allow that to happen. Are there 
any other general comments about the consequences of the use of cisplatin?
calvert: Just to continue on the theme of the late effects and the possibility of 
secondary tumours. One thing that has been very surprising over the last 20 years 
is that there are not nearly so many as we thought there would be, because the 
use of cancer chemotherapy has extended life so much with a large proportion 
of patients with breast cancer, for example, getting adjuvant chemotherapy, and 
then being cured, and available for follow-up for many years. I am not aware 
of any very significant reported increases in secondary tumours there, although 
they have had mutagenic agents. 
calman: I want to take up another couple of quick points before we finish.
Thomson: To follow up that point, I mentioned, ‘Haddow’s paradox’, but I 
think early on there were some studies done on the mutagenic power of cisplatin 
using the AMES test.169 If I remember rightly, it has a very low mutagenicity.
calvert: The other point relates to sperm banking and fertility. And that’s 
another thing that we have learnt, that infertility is less frequent than we 
thought it would be and the return to fertility is quite common, in men as well 
as women.
gralla: To echo the point of the long-term follow-up: I think that organized 
survivor clinics make a lot of sense. Not just to look at the issues of secondary 
malignancies, to look at long-term toxicities, neural toxicity; to look at issues 
of fertility, but also to look at psychological difficulties, learning defects, risk-
taking behaviours, in different individuals, and to do it in an organized way. 
This is something that we can all learn from, which will then help us to learn, 
long-term, to select the best regimes. It is possible that progression-free survival, 
which can be better, will be worse in certain groups and that overall survival will 
be better in others, especially if drugs have minor cardiac toxicity as people get 
older; this sort of thing. So I think a truly organized survivor clinic, not just a 
169 See, for example, Ames et al. (1973); McCann and Ames (1976).
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collection of data, can serve the patient with psychological, social and emotional 
needs, and can serve the medical community with a good way of keeping track 
of all these aspects. We have to look at it from an institutional point of view, 
just as you have suggested.
calman: What is interesting is that I chair a little group for Macmillan Cancer 
Relief here in the UK, looking at questions that patients want answered, to 
develop the research, and that was one of the ones that came out quite strongly. 
We want to have an idea about long-term survival and the issues and the 
problems etc., and that’s an area which has been developed.
Williams: May I make a general point, which is not on this subject? The general 
point is that it is very interesting that in the literature on the study of platinum 
compounds of various kinds, there is a very large number of them in the 
bioinorganic – or whatever you want to call it – biological inorganic chemistry 
journals such as the Journal of Bioinorganic Chemistry. Many of these compounds 
are claimed to be active. How on earth are they going to be tested? Meanwhile, 
we are developing a whole lot of other heavy metal complexes, which are also 
said to be anticarcinogenic; for example, there are a number of ruthenium 
compounds that have been tested on what I would call microbiological targets; 
in other words, they have gone through tests like the phage test,170 and the AMES 
test for mutagenicity of compounds. They have been tested to some degree in 
animal tests, and I don’t understand quite how the medical community is going 
to handle this material that’s coming into being. Are the chemists just wasting 
all their time? Are the chemists just producing 101 different compounds which 
have some effect, and we will never know if they are useful or not, because these 
studies are not concentrated or organized in any particular way? A huge amount 
of money is going into this work.
calman: May I say a few words to wind this up? Some of you probably don’t 
know, but one of my interests is in telling stories and I wrote a little book about 
three or four years ago about storytelling in medicine, and what we have heard 
today is a wonderful collection of stories which, in the jargon, illuminate the 
discovery and development of platinum. Could you, or would you do it again? 
Now? I suspect the answer is no, as I have listened to the way in which this has 
been developed. You wouldn’t get permission to do it, it would be difficult. 
Could you plan this? Planning scientific discovery? The answer must be pretty 
170 See page 19.
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close to no, which is quite interesting in terms of the funding of research. You 
can fund bits of it, but not all of it. So it’s quite interesting. Well, that’s what 
you have told us this afternoon. You can’t plan this. This is about people. What 
has also come through is the enormous courage of patients, we have heard that 
today, but I think the tremendous creativity and courage of staff too, from 
taking the pills to doing funny things with ferrets late at night. It’s an amazing 
range of things. 
I have just finished another little study on medical education,171 and one of the 
things that came out for me, was something that I have called medical magnets, 
or you could call them scientific magnets. That is, people who attract other 
people to work with them, and we have had a whole series, right at the beginning, 
with Rosenberg in Michigan, the Chester Beatty and the Marsden group, Ken 
Bagshawe’s group, the groups that were beginning and developed in the USA. 
They attract people, and they attract them because they have got something 
new to offer. They are hugely enthusiastic about what they do. People want to 
work with them. They have a global network. I mean Alex Haddow just flies 
backwards and forwards making these links, it’s amazing. Very hard-working all 
the time. They love teaching. They love supervising. They love having post-docs 
and PhD students, because that’s what it’s all about. And they have enormously 
open minds. Sir Peter Ustinov was Chancellor at the University of Durham just 
a year or two back, and he used to say, ‘Doubts unify, certitudes divide’. It’s a 
lovely phrase. If we are still prepared to doubt things, we can actually have a 
dialogue. But if I am sure that drug X really works, we won’t have a dialogue. 
And maybe that’s quite a nice way to finish this. 
I have had a really good day; I have listened to some wonderful stories. I think this 
is going to make an excellent volume, and there are some big lessons for science 
and medicine, and its development. On your behalf, may I thank Tilli and all the 
staff who have walked about with microphones, and done other things, to make 
a very interesting afternoon? So, on your behalf, we thank them.
Tansey: May I just make a final comment please? I would like to echo something 
that John Rudd said earlier, that it has been a privilege to be here this afternoon 
and to hear these stories and accounts. But they are not just stories, these are 
the building blocks of history and we have a serious purpose in holding these 
meetings, to record them, to transcribe, edit them, and to make them widely 
171 Calman (2006). See also Reynolds and Tansey (eds) (2007).  
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available to people – your colleagues in clinical oncology and pharmacology, my 
colleagues in the history of medicine. We are extremely grateful to all of you for 
coming along and contributing your stories and, on your behalf, I would also 
like to thank Sir Kenneth Calman for his excellent chairing. 
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Appendix 1 
in praise of methotrexate 
by professor sir kenneth calman 
I want to tell a story of some anti-cancer drugs,
So sit back, charge your glasses, and pin back both your lugs.
It all began with Ehrlich, of ‘magic bullet’ fame,
Back in the 1890s when science was just a game.
He synthesized an alkylator ethylenimine,
The first true cytotoxic the world had ever seen.
A space of 40 years elapsed, until in time of war
The ship, the John F Harvey sank down in Bari Harbor.
Aboard this ship was mustard gas – its effects the Bard recites
Made many of the men right sick and dropped their leucocytes.
The medic, Alexander, had a flash of inspiration
That clinical benefit might result when the white count showed elevation.
So Goodman and Gilman and Dougherty from the field of Academia
Assessed the use of mustard in childhood and adult leukaemia.
And so the scene is set, Sidney Farber’s on the stage.
The drug was methotrexate and chemotherapy came of age.
Aminopterin was first, or so the Bard relates,
Both compounds being active as synthetic antifolates.
The drug is given orally or by the intravenous route,
Intramuscularly, intrathecally, which ever one will suit.
Its pharmacokinetics fit a three compartment system.
It has three half-lives in venous blood, but I do not wish to list ’em.
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Its mechanism of action, its biochemical pharmacology
Have been described for many years and are like dogma in oncology.
Methotrexate acts, or so the Bard oft says
On a critical enzyme molecule, dihydrofolate reductase.
It has a very high affinity 10-8 or more





Enzyme action is inhibited at micromolar concentration,
Always of course assuming adequate drug penetration.
Other enzymes are important like carboxypeptidase,
Hepatic aldehyde oxidase and thymidylate synthetase.
Thymidine kinase is another catalyst,
The others have much longer names I will not even list.
Its action on the cell cycle is really quite terrific
Like some other antimetabolites methotrexate is S-phase specific.
Methotrexate does exist in many different states
And currently the interest is in polyglutamates.
There are monoglu’s and diglu’s and glu’s to the power N,
Their significance, however, is quite beyond my ken.
To measure methotrexate is not an easy task.
Which methods are the best ones do I hear you ask?
Well there’s GLC, HPLC and radioimmunoassay,
And EMIT kits of course which are actually rather classy.
Some techniques at first were really rather primitive
And couldn’t even measure the 7-hydroxy derivative.
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The side-effects of methotrexate must not be forgotten.
Mucositis is perhaps the worst in fact it’s rather rotten.
Renal damage may result and can accentuate toxicity,
Hepatic damage can occur when its given with some chronicity.
Sore eyes can be a problem and reddened conjunctiva,
Methotrexate is secreted in the tears and in saliva.
One side-effect, however, which has not been documented
Is car-cin-o-genesis which makes one quite contented.
So far the evidence suggests, and the Bard has not heard rumours,
That methotrexate, given long term, does not cause second tumours.
Before I bring this rambling verse to a necessary close,
I must mention methotrexate given in mega dose.
Instead of 15 mg, we now use 15 g.
And such dose can be repeated, in fact ad nauseam.
Folinic acid rescue is the secret of success,
Without old leucovorin we’d be in quite a mess.
Well I’m getting tired now and on my feet I teeter,
But before I end this rhyme I should like to change the metre
Because
You can flatten ’em with platinum.
Get big cell kill from fluorouracil
Be a medicine man with melphalan
Keep things pristine with vincristine.
Shout with glee with 6MP.
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Quite amaze with asparginase.
Be a boss with cyclophos.
Never be alone with prednisone.
But don’t touch custard after mustard.
Play to win with doxorubicin.
But you can fix it with methotrexate.
My verse it must now terminate.
I ask you all to celebrate.
Your glasses raise to participate
And with one voice expostulate
IN PRAISE OF METHOTREXATE.
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Appendix 2
structures of some 5hT
3
 receptor antagonists
Ondansetron (1), GR 65,630 (2), tropisetron (3), granisetron (4), zacopride 
(5), and renzapride (6).
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Appendix 3
components of the emetic reflex 
Major components of the emetic reflex believed to be involved in emesis evoked 
by cytotoxic therapy or by orally ingested toxins.
Adapted from Andrews et al. (1988): 335. 
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cisplatin-induced acute and delayed 
emesis and revealed the potential 
of NK
1
 receptor antagonists to 
reduce delayed emesis. He moved 
to the Chinese University of Hong 
Kong in 1995. He currently has an 
Emesis Research Group that has 
strong links with industry.
Dr gareth sanger
(b. 1953) was Research Fellow at 
King’s College Hospital Medical 
School, London (1977–90), and 
scientist and manager within the 
different companies now represented 
by GlaxoSmithKline. He was 
jointly awarded (with Dr M Tyers) 
the 1998 Pharmaceutical Research 
and Manufacturers of America 
(PhRMA) Discoverer’s Award for the 
5HT
3
 receptor/antiemesis research 
which led to the identification 
and development of Kytril®. His 
current expertise is in the biology of 
ghrelin, motilin, 5HT, tachykinins 
and other areas. He is editor and 
reviews editor for the British Journal 
of Pharmacology and editorial board 
member for Drug Discovery Today.
Dr Tilli Tansey
HonMRCP FMedSci (b. 1953) 
is Convenor of the History of 
Twentieth Century Medicine 
Group and Reader in the History 
of Modern Medical Sciences at 
the Wellcome Trust Centre for the 
History of Medicine at UCL.
Dr David Tattersall
(b. 1961) has been involved in 
the development of antiemetic 
drugs for over 20 years. During 
his PhD studies he worked in the 
Neuropharmacology Laboratory 
of Professors Robert Naylor and 
Brenda Costall, investigating 
the control of vomiting. It was 
during these studies that the 5HT
3
 
receptor antagonists were shown to 
inhibit emesis induced by cisplatin 
[Costall et al. (1986)]. He moved 
to the laboratories of Dr Richard 
Hargreaves and Professor Ray 
Hill at Merck Sharp & Dohme 
in Harlow. The most recent 
treatments for chemotherapy-
induced emesis, the Substance 
P (NK
1
) receptor antagonists, 
were developed during this time 
[Tattersall et al. (2000); Hesketh et 
al. (2003)]. He has been head of a 
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preclinical in vivo biomarkers and 
translational biology group at Pfizer 
in Kent, since 2006.
professor andrew J Thomson
FRSC FRS (b. 1940) graduated 
from Oxford in 1965, obtaining 
his DPhil under the supervision 
of Professor Robert Williams. In 
the Department of Biophysics, 
Michigan State University (MSU), 
working with Professor Barnett 
Rosenberg, he discovered the 
biological effects of cisplatin and 
also studied models of visual 
pigments. He joined the School of 
Chemical Sciences at the University 
of East Anglia (UEA) in 1967, 
where he has remained ever since. 
With Professor Colin Greenwood 
he established an interdisciplinary 
unit, the Centre for Metalloprotein 
Spectroscopy and Biology 
(CMSB), studying the structures 
and functions of the proteins of 
bacterial respiratory chains. He 
has developed novel magneto-
optical techniques to inspect the 
metal cofactors employed by such 
proteins. In 1985 he was appointed 
Professor of Chemistry. From 1998 
he served as Head of the School 
of Chemical Sciences for five years 
and founded the first new School of 
Pharmacy in the UK for 30 years, 
jointly with Chemical Sciences. He 
became the founding Dean of the 
Faculty of Science at UEA in 2002.
professor martin leslie Tobe
(1930–93) was Lecturer  
(1956–65), Reader (1965–71) 
and Professor (1971–93) at the 
Department of Chemistry, UCL. 
His research centred on the 
mechanisms of substitution of 
transition metal complexes.  
He won the Corday-Morgan  
Medal of the Chemical Society 
(now the Royal Society of 
Chemistry) in 1963.
sir peter Ustinov 
Kt CBE FRSA FRSL (1921–2004), 
British-born actor and writer, was 
Chancellor at Durham University, 
from 1992; Rector of the 
University of Dundee from 1971 to 
1973 and goodwill ambassador for 
UNICEF in 1969.
Dr loretta van camp
(1948–2006) was co-discoverer 
with Drs Barnett Rosenberg and 
Thomas Krigas of the anti-cancer 
drug, cisplatin [Rosenberg et al. 
(1965)]. She received an Honorary 
Doctor of Science from MSU  
in 1999. 
professor robert (Bob) Williams
FRSC FRS (b. 1926) worked from 
1948 in the Inorganic Chemistry 
Laboratory at Oxford on the role 
of metal ions in biological systems. 
He has been a Fellow of Merton 
College, Oxford (1951–55) and 
Wadham College, Oxford (1955–) 
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and successively Lecturer, Reader 
(1955–74) and Napier Royal 
Society Research Professor  
(1974–91). His work is 
summarized in Williams and 
Phillips (1966); Williams and 
Fraústo da Silva (2001, 2006).
Dr eve Wiltshaw
OBE FRCP FRCOG (b. 1927) 
qualified in 1952 from the 
University of Wales and researched 
clinical haematology in Boston, 
Massachusetts, USA, from 1953 
to 1955. She joined the Institute 
of Cancer Research and the Royal 
Marsden Hospital in 1955 to 
work on drug treatment of cancer 
patients and was Medical Director 
there from 1986 to 1994. She is 
known for the introduction of 
cisplatin and carboplatin into 
clinical practice in the UK. See 
Wiltshaw (1998).
106
The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer – Glossary 
biomaterial
Material used to construct artificial 
organs, rehabilitation devices or 
prostheses, and to replace natural 
body tissues.
brachytherapy
A procedure in which radioactive 
material sealed in needles, seeds, 
wires or catheters is placed directly 
into or near a tumour. 
bradycardia
A slow heart rate, usually defined  
as less than 60 beats per minute.
cannabinoid
Any of various organic 
substances, such as THC 
(tetrahydrocannabinol), found  
in cannabis.
choriocarcinoma
A malignant tumour of 
syncytial trophoblasts and 
cytotrophoblasts, almost always 





chemotherapeutic drug used to 
treat metastatic ovarian or testicular 
cancers and advanced bladder 
cancer, and head and neck tumours. 
creatinine clearance 
A method that estimates the 
glomerular filtration rate (GFR) 
of the kidneys; the amount of 
liquid filtered out of the blood 
that gets processed by the kidneys. 
Clearance is measured in ml/min. 
The lower the creatinine clearance, 
the less effective is the working 
of the kidneys. Normal values are 
between 100 and 140 ml/min.
cytotoxic
Of, relating to, or producing a toxic 
effect on cells.
electrolyte
A chemical compound that ionizes 
when dissolved or molten to 
produce an electrically conductive 
medium.
electrophoresis
A process by which molecules, 
such as proteins, DNA or RNA 
fragments, can be separated 
according to size and electrical 
charge by applying an electric 
current to them. Each kind of 
molecule travels through the 
medium at a different rate, 
depending on its electrical charge 
and molecular size. 
Glossary*
* Terms in bold appear in the glossary as separate entries
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enterochromaffin (ec) cells 
Cells that occur in the epithelial 
lining of the lumen of the 
gastrointestinal tract. They produce 
and contain about 90 per cent 
of the body’s store of serotonin 
(5HT).
etoposide phosphate (eposin®, 
etopophos®, vepesid®, vp-16®) 
An inhibitor of the enzyme 
topoisomerase II. It is used as 
a form of chemotherapy for 
malignancies such as lung cancer, 
testicular cancer, lymphoma, 
non-lymphocytic leukaemia and 
glioblastoma multiforme. It is often 
given in combination with other 
drugs, for example, cisplatin.
exocytosis
A process of cellular secretion or 
excretion in which substances 
contained in vesicles are discharged 
from the cell by fusion of the 
vesicular membrane with the  
outer cell membrane.
filamentation 
Anomal growth of certain  
bacteria, such as E. coli, in which 
cells continue to elongate but do 
not divide. Bacterial filamentation 
is a defect in the completion of 
replication and is observed in 
bacteria responding to various 
stresses, for example, while 
responding to extensive  
DNA damage.
glomerular filtration rate (gfr)
The quantity of glomerular 
filtrate formed each minute in the 
nephrons of both kidneys, usually 
measured by the rate of creatinine 
clearance.
half-life
Measurement of the amount 
of time it takes for half of the 
radioactive atoms in an element to 
decay. For material with a half-life 
of one week, half of the original 
amount of activity will remain after 
one week; half of that (one-quarter 
of the original amount) will remain 
after two weeks and so on.
hepatoblastoma 
A form of liver cancer that usually 
occurs in infants.
isomers
Molecules with the same chemical 
formula and often with the same 
kinds of bonds between atoms, but 
in which the atoms are arranged 
differently; that is, they have 
different structural formulae. 
lysis
The dissolution or destruction of 
cells, such as blood cells or bacteria, 
by the action of a specific lysine.
methotrexate (amethopterin)
A toxic antimetabolite that acts 
as a folic acid antagonist, used as 
an antineoplastic agent and in the 
treatment of rheumatoid arthritis 
and psoriasis. 
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metoclopramide
A potent dopamine receptor 
antagonist and a 5HT
4
 receptor 
agonist used in treatment of 
patients with delayed gastric 
emptying. It is also useful for 
facilitating small bowel intubation 
and as an antiemetic. The 
most common side-effects are 
somnolence, nervousness and 
dystonic reactions.
pro-drug
A drug that enters cells more easily 
and once there, is converted to the 
desired active molecule.
radiotherapy
The treatment of disease with 
ionizing radiation. Also called 
radiation therapy.
seminoma
A malignant tumour of the testis 
arising from sperm-forming tissue.
serotonin (5-hydroxytryptamine, 
or 5hT) 
A monoamine neurotransmitter 
synthesized in serotonergic 
neurones in the central nervous 
system and enterochromaffin cells 
in the gastrointestinal tract.
stereoisomer
An isomer whose bond structure 
is the same but whose atomic 
arrangement in space is different.
tubular secretion
Transfer of materials from 
peritubular capillaries to the renal 
tubular lumen.
von Bezold–Jarisch reflex
A cardiovascular decompressor 
reflex involving a marked increase 
in vagal (parasympathetic) efferent 
discharge to the heart, arising from 
stimulation of chemoreceptors, 
primarily in the left ventricle. This 
causes a slowing of the heart beat 
(bradycardia) and a dilatation 
of the peripheral blood vessels, 
which results in the lowering of the 
blood pressure. The concept was 
originated by von Bezold in 1867, 
and later revised by Jarisch in 1937.
Wilm’s tumour 
A neoplasm of the kidneys that 
typically occurs in children. It is 
also known as a nephroblastoma.
X-rays 
Invisible, highly penetrating 
electromagnetic radiation of a 
much shorter wavelength than 
visible light, discovered in 1895  
by Wilhelm Röntgen. 
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adriamycin, 71
AFP (alpha fetoprotein), 6
alkylating agents, 13, 22–3, 24, 26, 36
alpha fetoprotein (AFP), 6
AMD473 (picoplatin), 12, 24
American football match, 21
American Society of Clinical Oncology 
(ASCO), 33




platinum see AMD473, picoplatin





 receptors and ligands, 50–2, 
59
cisplatin, 9, 13–14, 32
emesis, 34, 35–6, 44, 64–6
necessity for, 55, 57
see also ferret emesis model
antiemetic agents, xxiii, 3, 44–69
in clinical practice, 66–8
costs, 59, 60–2, 67–8
measuring efficacy, 47
rationale for developing new, 46–7





area under the curve (AUC), 28
arsenic, xxiv, 3, 41
AUC (area under the curve), 28
ASCO see American Society of Clinical 
Oncology
bacteria
filamentous growth see 
filamentation, bacterial
phage release, 19, 20
see also Escherichia coli
Beecham Pharmaceuticals/Research 
Laboratories (now part of 
GlaxoSmithKline), 44–5, 52, 53, 
54
behavioural models, animal-based, 
51–2, 59




bleomycin, 31, 33, 72, 73
blister-base pain model, 51
boron, xxiv
brachytherapy, 106
Bradford, 45, 57–9, 61, 63–4, 65
Bradford Telegraph and Argus, 59, 61
bradycardia, 51, 106
brain tumours, 70
breast cancer, 67, 74
Bristol-Myers (Squibb), NY, 3, 29–30, 
35–6, 37
British Pharmacological Society, 64
BRL 43694 see granisetron
Brock grading system, 42, 44
Calvert formula, xxiii, 28–9, 44
cancer patients
cisplatin-treated, 5, 42, 46–7, 71–2
5HT
3
 receptor antagonist-treated, 
54, 59
information provision to, 5–6, 71
long-term follow-up, 72–5
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Cancer Treatment Reports, 43
Cancerbackup, 70
cannabinoids, 47, 106
carboplatin, xxiii, xxiv, 23–4, 27–30, 
34, 62
chemical structure, 12
clinical utility, 28–9, 43–4, 46
Phase 1 trial, 27–8, 40–1
toxicity, 28, 70
versus cisplatin, 29, 30, 43
chemiosmosis, 16
The Chemistry of Evolution (Williams 
and da Silva), 15
Chester Beatty Research Institute, 





 receptor antagonists, 59–60, 
67
cisplatin therapy, 41–3
high-dose metoclopramide, 48, 60
long-term toxicity, 69, 70, 73–4
CHIP see iproplatin
chlorambucil, 22, 26
chloride ions, 8, 13, 36
choriocarcinoma, 32, 38–9, 106
Ciba Foundation Symposium, 16
cisplatin (cisplatinum, cis-platin), xxiii, 
4, 106
as bifunctional reagent, 11, 13
chemical structure, 12
chemistry, 6, 8–13, 21, 37–8
clinical studies, 23, 24–6, 27, 31, 
32–3
clinical use, 5, 43–4
development, 8–15
early US attitudes to, 19, 23, 26
emetic effects see emesis
long-term sequelae, 72–5
mannitol and hyperhydration, 32, 
34–5
mechanism of action, 12, 18–19, 
36, 37–8, 68–9




preclinical studies, 9, 13–14, 41
renal toxicity see renal toxicity
role in antiemetic drug 
development, 46–7
synthesis, 9, 11
toxicity, xxiii–xxiv, 4, 42–3
versus carboplatin, 29, 30, 43
clinical oncology see medical oncology
clinical trials (including Phase I and II 
trials), 24–33
carboplatin, 27–8, 30, 40–1
cisplatin, 23, 24–6, 27, 31, 32–3
early US, 3, 19, 23, 26, 30
5HT
3
 receptor antagonists, 59–60
lack of restrictions in 1970s, 25
combination therapy, 36
corticosteroids (glucocorticoids), 48–9, 
64, 66
see also dexamethasone
costs, antiemetic agents, 59, 60–2, 
67–8








‘death-watch beetles’, 25, 26
dexamethasone, 49, 61, 64, 66, 67
cis-diammine (1,1-
cyclobutanedicarboxylato) 
platinum (II) see carboplatin
diamminodichloro platinum (II), cis 
and trans isomers, 9, 11














diuresis, forced (osmotic), 32, 34–5
DNA
modes of binding to, 12, 36
platinum compound actions, 18–19, 
28








drug industry see pharmaceutical 
industry
dystonic reactions see extrapyramidal 
side-effects
E. coli see Escherichia coli
electrolysis, bacterial suspensions, 7, 
16–17, 20–1
electrolyte, 106
electron transfer systems, 16, 17, 20
electrophoresis, 106
curtain, 8
emesis (vomiting), 4, 44–69
animal models, 34, 35–6, 44, 64–6
carboplatin-induced, 28
conditioned reflex, 6
delayed, 44, 48, 49, 59, 60, 64–5
ferret model see ferret emesis model
fluid administration for, 26
gastric stasis model in rodents, 34, 
35–6
mechanism of induction, 68–9
patient’s experience, 72
rates in patients, 47, 48, 49, 66–7
reflex, 83
see also antiemetic agents
enterochromaffin cells, 68–9, 107
Eposin® see etoposide
Escherichia coli (E. coli)
filamentous growth, 7, 8, 10, 13, 22
phage release, 19
Etopophos® see etoposide
etoposide, 40, 73, 107
exocytosis, 68–9, 107
extrapyramidal side-effects (dystonic 
reactions)
anecdote, 71
in children, 48, 60
developing drugs without, 52, 57–8, 
66–7
FDA (Food and Drug Administration), 
23
ferret emesis model, 34, 36, 44, 53, 59
5HT
3
 receptor antagonists, 45, 
53–4, 55–7
acute and delayed phase, 64–6
ferret video, 56–7, 62
fertility, 6, 72, 74
filamentation, bacterial, 107
antitumour activity and, 13, 20
magnesium-induced, 22
platinum-induced, 7, 8, 9, 20–1
fluid administration see hydration
Food and Drug Administration (FDA), 
23
Franklyn Jail, prisoner from, 40–1
Friedman test, 39
funding, research, 5, 25
gastric prokinetic activity, 52–3, 58, 62
gastric stasis (bloat) rodent model, 34, 
35–6
germ cell tumours, 32, 40
see also teratomas
gestational trophoblastic tumours, 
39–40, 73
see also choriocarcinoma
GFR see glomerular filtration rate
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Glasgow, 4, 5–6, 26–7, 71
Glaxo (now part of GlaxoSmithKline), 
45–6, 51, 54, 59–60, 61, 65
GlaxoSmithKline plc, 51, 52
glomerular filtration rate (GFR), 28, 
35, 42, 72, 107
glucocorticoids see corticosteroids
gold, xxiv
Gone with the Wind (Mitchell), 18
GR 38032F see ondansetron
GR 65,630, 82
granisetron, 4, 54, 82
Great Ormond Street Hospital, 
London, 41–3, 71–2, 73–4
guinea-pig, 58
Haddow’s paradox, 14, 74
half-life, 107
Harvard University, 17, 18
head and neck cancer, 26, 31
health and safety, 70–1






HPLC (high-performance liquid 
chromatography), 64
5HT see serotonin
5HT receptors, classification, 49
5HT
3
 receptor antagonists, 44–5, 46, 
49–69





ferret studies, 45, 53–4, 55–7, 59
mechanism of action, 62–3
see also specific agents
5HT
3
 receptors (originally 5HT M 




hydration (fluid administration), 26, 
32, 34–5, 43, 72
5-hydroxytryptamine (5HT) see 
serotonin





ICS 205-930 see tropisetron
immune system, 18
In Praise of Methotrexate (Calman), 
4–5, 78–81
infertility see fertility
Institute of Cancer Research, Sutton, 
54
International Childhood Liver Tumour 
Strategy Group (SIOPEL), 42–3
International Symposium on Platinum 
Coordination Complexes in 
Cancer Chemotherapy
first (1971), Michigan, 21
second (1973), Oxford, 9, 19, 26, 
30–1
iproplatin (JM9), 12, 27, 34
isomers, 107
Japan, 28–9, 54, 64–5
JM see Johnson Matthey
JM8 see carboplatin
JM9 (iproplatin), 12, 27, 34
JM216 (satraplatin), 12, 24, 62
Johnson Matthey (JM), 4, 14, 21, 30
Journal of Bioinorganic Chemistry, 75
Journal of Biological Chemistry, 9
Journal of Clinical Oncology, 29
Jumbo (rugby game), 24
Kytril® see granisetron





liver tumours, childhood, 42–3
long-term sequelae, 69, 70, 72–5
lung cancer, 29, 43, 46
lysis, 13, 107




mannitol, 32, 43, 70
marketing, drug, 29, 61, 67
MDL 72222, 50, 53–4
medical (clinical) oncology, 25, 29, 
30, 38
Medical Research Council (MRC), 21, 
23
meetings, scientific, 24, 41
see also Oxford meeting (1973)
melphalan, 22
Memorial Sloan-Kettering Cancer 
Center, New York, 30–1, 32–3, 
70
6-mercaptopurine (6-MP), 39
mercury, xxiv, 3, 41
Merrell Dow, 50, 53
metal ions, in biology, 15–16, 18
metals, medical use, xxiv, 3
methotrexate, xxiv, 27, 32, 40, 61, 107
Calman poem, 4–5, 78–81
metoclopramide, 61, 108
high dose, 45–6, 47–8, 49, 55, 60
mechanism of action, 52–3
side-effects see extrapyramidal side-
effects
mice, 9, 13–14, 21, 34, 35, 44
Michigan State University (MSU), MI, 
3–4, 20, 21, 37, 76
migraine, 50, 51, 52
6-MP (6-mercaptopurine), 39
MRC see Medical Research Council
MSU see Michigan State University
mutagenicity test, AMES, 74, 75
myeleran, 22
myelosuppression, 28
Napier Research Professorship, Royal 
Society, 18
National Cancer Institute (NCI), 9, 
15, 21, 30, 31





NCI see National Cancer Institute
Neosalvarsan, xxiv
nephroblastoma see Wilms’ tumor
nephrotoxicity see renal toxicity
neurological toxicity, 26, 43
Neuropharmacology Research Group, 
Bradford, 57–9, 61
nickel, 14




 receptor antagonists, 44, 49, 58, 
63, 67
Novartis, 51
oncology see medical oncology; 
paediatric oncology
ondansetron, 4, 51–2, 54, 64
chemical structure, 82
paediatric study, 59–60
OPB (Paediatric Oncology Group of 
Benelux), 59–60
ototoxicity (hearing loss), 42, 43, 
69–70
ovarian cancer
carboplatin, 27, 29, 30
cisplatin, 5, 25–6, 30, 31, 40, 43
oxaliplatin, xxiv, 43
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Oxford meeting (1973), 9, 19, 26, 
30–1
Oxford University, 7, 17–18, 19–20
oxygen tent, 38–9
paediatric oncology, 41–3, 59–60, 69
see also children





patients, cancer see cancer patients
persistent internal polarization, 37
Peter Bent Brigham Hospital, Boston, 
MA, 17
Peyrone’s chloride, 9
phage, bacterial release, 19, 20
pharmaceutical industry, 49, 51–4, 
58–9, 61–2, 67, 69
see also specific companies
Pharmaceutical Research and 
Manufacturers of America 
Association (PhRMA), 52
pharmacoeconomics, 61–2, 67–8
pharmacokinetics, 28, 34–5, 63
Phase I and II trials see clinical trials
phenothiazines, 47
photochemical reaction, 8, 10
PhRMA see Pharmaceutical Research 
and Manufacturers of America 
Association
picoplatin (AMD473), 12, 24
pigeons, 64–5
platinum, xxiii, 3
chemistry, 7–9, 17, 21
effects on E. coli, 7, 8, 10
electrodes, 3, 7, 16–17
oxidation states (II and IV), 7, 10
platinum compounds
bioinorganic chemistry literature, 75
mechanism of action, 12, 18–19, 68
orally available, 24, 34, 62
second generation, 12, 23–4, 27, 
29–30, 33–4
synthesis studies, 9, 20, 21
see also carboplatin; cisplatin; other 
specific compounds











radiotherapy, 26, 70, 108
rats, 27, 34, 44, 50–1, 53
renal function
carboplatin toxicity and, 28–9
long-term effects of cisplatin, 72, 
73–4
renal toxicity, 26, 28
chemical reactivity and, 34
mechanisms, 36
protective therapy, 31–2, 34–5, 43
renzapride, 62, 82
Research Corporation (now Research 
Corporation Technology), 37
A H Robins Company, 57–8
rodents, stomach bloat, 34, 35–6
Royal Marsden Hospital, Sutton, 4, 
23, 27, 76
Royal National Institute for the Deaf, 69
Royal Society, 18
rugby football game (Jumbo), 24
Rustenburg Platinum Mines, 14
ruthenium compounds, 75
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Salvarsan, xxiv
Sandoz (now part of Novartis), 51, 58
sarcoma 180 mouse model, 9, 13–14
satraplatin see JM216




cisplatin-induced release, 60, 68–9
receptors see 5HT receptors
Serotonin Club meeting (1992), 65
silver, xxiv
SIOPEL (International Childhood 
Liver Tumour Strategy Group), 
42–3
Smith Kline Foundation, 44
sodium thiosulfate (STS), 69–70
spectroscopy, 17
sperm storage, 6
St Mary’s Hospital, London, 38
stereoisomers, 8, 108
stomach bloat (stasis) in rodents, 34, 
35–6
structure–activity studies, 21, 34
STS (sodium thiosulfate), 69–70




sulphur mustard, 12, 13
support groups, patient, 70
survivor clinics, 74–5
syphilis, xxiv
Tak Tent groups, 70
teratomas, 5–6, 40, 71
see also germ cell tumours
testicular tumours, 39–40
cisplatin, 5, 26, 31, 32–3, 35, 43
long-term sequelae of treatment, 73












tropisetron (ICS-205-930), 4, 51, 58, 
82
tubular secretion, 35, 108
UEA see University of East Anglia
United States (US), 3–4, 13–15, 19–
20, 23, 29
University of East Anglia (UEA), 
Norwich, 6, 7–8
VAB-3 chemotherapy protocol, 33
Vepesid® see etoposide
vinblastine, 33, 46, 72, 73
vinca alkaloids, 46
vomiting see emesis
von Bezold–Jarisch reflex, 50–1, 108
VP-16® see etoposide
Wellcome Trust, London, 3, 5, 6–7
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